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1. AIMS 
1.1) Primary objectives: 
1. To assess the feasibility and toxicity of hyperthermia along with radiation in patients with 
locally advanced non metastatic head and neck cancers 
2. To assess the palliation of distressing symptoms in locally advanced head and neck cancers 
treated with palliative intent 
3. To assess the duration of treatment in comparison with the standard of care, which is usually   
six weeks 
1.2) Secondary objective: 
To assess the efficacy of this modality in terms of disease response as weekly clinical 
assessment, at the end of treatment and at three months. 
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                                                        2. INTRODUCTION 
Head and neck cancers are the sixth most common cancers worldwide (1). They are responsible 
for significant morbidity and mortality rates, more in developing countries.  The major risk 
factors are smoking, tobacco consumption, human papilloma virus (HPV) infection, Epstein barr 
virus (EBV) infection. Most of the incidence of these cancers in various parts of the country is 
related to the risk factors prevalent in those regions, indicating the need for cancer education and 
screening campaigns.  Most of the Indian patients present with locally advanced malignancies to 
the hospitals.  The standard treatment option is multimodality regimen with surgery, radiotherapy 
and chemotherapy. Surgery in most cases is not possible due to inoperability, lack of technical 
facilities and associated comorbidities.  
 Radiotherapy has been the standard non-surgical treatment modality for head and neck cancers.  
Radiotherapy has evolved from once daily conventional fractionation to accelerated fractionation 
and hyper fractionation (2–4). These newer strategies led to a 7 % to 10 % improvement in local 
control relative to once daily regimens.   
Hyper fractionation had demonstrated 8 % absolute improvement in 5 year survival (5).  
However, the most effective radiotherapy regimens have resulted in local control of 50% to 70 % 
and disease free survival of 30 % to 40 % in these patients.  Later on it was found that 
chemotherapy when added to radiotherapy acted as a radio sensitizer, and had led to increased 
local control and improved disease free survival and overall survival.  The commoner 
chemotherapeutic agents used in head and neck cancer are Cisplatin, Carboplatin, 5 Flourouracil, 
Docetaxel, and Methotrexate. Many randomized trials have shown that combined chemo 
radiation is superior to radiotherapy alone in the treatment of locally advanced, non-metastatic 
head and neck cancers.  Meta- analysis of radiotherapy and concurrent chemotherapy (MACH 
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NC) demonstrated that the use of radiotherapy and concurrent  chemotherapy resulted in 19 % 
reduction in the risk of death and an overall improvement of 6.5 % overall survival (6).  Chemo 
irradiation has also proven to be successful in organ preservation (7). Randomized comparisons 
of concurrent chemo irradiation versus induction chemotherapy followed by radiotherapy alone 
are few but confirm that the former strategy is superior.  
Radiotherapy and concurrent chemotherapy is the recommended and most commonly practiced 
treatment modality in locally advanced head and neck cancer due to the radio sensitization 
concept and the proven benefit in local control, disease free survival and overall survival. 
But concurrent chemotherapy has its own acute toxicities and might delay the total duration of 
radiotherapy which is of prime concern. The most commonly used drug Cisplatin causes 
nephrotoxicity, hematological abnormalities and electrolyte disturbances.   Majority of our 
patients are not fit for administration of chemotherapy due to poor general condition, low 
creatinine clearance, associated comorbid illnesses and lack of finances to procure chemotherapy 
drugs and also manage the toxicities.   It is often found that many of these patients are unable to 
complete the planned radiotherapy within the recommended duration because of chemotherapy 
related   toxicities. In view of this, patients might not benefit from the addition of chemotherapy. 
There is definitely a need for an alternative modality in the treatment of this subset of patients 
who are unfit or unable to undergo chemotherapy along with radiotherapy. Most of these patients 
end up being treated with radiotherapy alone which might not be effective due to advanced 
nature of disease and the presence of hypoxic clone of cells. Hyperthermia is known to be 
beneficial in these hypoxic tumours as they act mainly by direct cytotoxicity and DNA damage. 
Due to unorganized and poorly formed vasculature, the heat from the tumour is poorly 
disseminated which leads to additional 
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cytotoxicity. There are various randomized controlled trials which prove the benefit of 
hyperthermia when used along with radiotherapy.  
Therefore we have conducted a pilot study to evaluate the feasibility, tolerance and efficacy of 
addition of hyperthermia to external beam radiotherapy on patients with locally advanced non 
metastatic inoperable head and neck cancer for palliation of symptoms. 
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2.11 EPIDEMIOLOGY:  
Head and neck cancers account for more than 5,55,000 cases  annually worldwide (8).  In the 
United States, they account for about 3 % to 5 %, with an estimated 53,000 Americans 
developing head and neck cancer annually and 11,500 dying from the disease (9).  Males are 
more commonly affected than females, the ratio being 4:1. They account for 23 % of all cancers 
in males and 6 % in females. The incidence rate in males exceeds 20 per 100,000 in the countries 
of Hong Kong, Indian subcontinent, France, Spain, Brazil, central and Eastern Europe, Italy and 
among African Americans in the Unites States.  In the Indian subcontinent, incidence of cancers 
of oral cavity is more due to the prevalent habits and addictions. The incidence of 
nasopharyngeal cancers is more in the country of Hong Kong, and laryngeal, pharyngeal cancers 
are more common in other populations (10). 
The incidence of laryngeal cancer, but not oral cavity and pharyngeal cancer, is approximately 
50 percent higher in African American men (11). 
2.12 HEAD AND NECK CANCER IN INDIA: 
Head and neck cancers in India have a distinct demographic profile, different risk factors and are 
emerging as a major public health burden. Highest priority should be given to head and neck 
cancers in India and management guidelines should be formulated according to the limited 
resources in the country and social status of the patients. Overall 57.5 % of global head and neck 
cancers occur in Asia especially in India. Head and neck cancers contribute to 60 % of all 
cancers in males except in Dibrugarh in Assam (49.6%).  Tongue and mouth cancers contribute 
to more than one third except in Dibrugarh where hypopharynx is more common. In females 
head and neck cancers contribute to 11 to 16 % of all cancers and mouth cancers are more 
common in them. Nearly 80,000 oral cancers, 40,000 cases of pharyngeal cancers and 29,000 
cases occur each year in India. 
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2.13 EVALUATION OF HEAD AND NECK CANCERS:   
Initial evaluation starts with a good history and clinical examination.  An indirect laryngoscopy, 
nasopharyngolaryngoscopy should be done to define the extent of the primary as well as to rule 
out any synchronous lesions.  Biopsy from the lesion is mandatory prior to treatment. Chest x ray 
is mandatory in all patients.  Routine bloods should be done and to assess the general condition 
of the patient. 
Computed tomography scan (CT) with intravenous contrast is more useful for appropriate 
staging, precise delineation of the tumour, infiltration of the surrounding structures, and to detect 
nodal metastases.  It helps in deciding regarding operability.  
Magnetic resonance imaging (MRI) is more informative in proper soft tissue resolution, to rule 
out base of skull infiltration, invasion of cartilages and detection of early lesions. 
In patients diagnosed to have nasopharyngeal cancers bone scan is done as a part of workup to 
rule out skeletal metastases. 
In head and neck cancer PET CT is an emerging diagnostic tool. It has a detection rate between 
88 % and 98%  for head and neck primary tumours and has a higher sensitivity than CT or 
MRI(12).  It has been found to alter the TNM staging in 15 % to 36 % of patients compared to 
CT/MRI staging. Because of the greater sensitivity for detection of metastatic lesions this may be 
used for staging and detection of synchronous second primaries in appropriately selected patients 
who have more than 10 % risk for distant metastases. These include patients with bilateral nodes, 
level 4 nodes, more than 4 lymph nodes, nodes larger than 6 cm in and recurrent tumours (13). 
But due to the false positive rates of 20 % and because of the relatively small number of patients 
in the studies, the PET findings need to be correlated with histopathological confirmation (14).  
PET CT is a very useful tool in the workup of unknown primary and also has been a very useful 
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tool for follow up in post radiotherapy patients especially when they are planned for salvage 
surgeries.  
2.14 TREATMENT STRATEGIES: 
Locally advanced head and neck cancers (stage III, stage IV A, stage IV B) constitute about 50 
% of the cases which pose a clinical challenge and require aggressive treatment. Surgery, 
chemotherapy and radiotherapy are the various treatment modalities in head and neck 
malignancies. 
 a) SURGERY:  Surgery is the single modality treatment in early oral cancers. Function 
preserving surgeries are performed in selected cases of oropharyngeal cancers and hypo 
pharyngeal cancers. Surgery is done first in locally advanced laryngeal cancers if they are not 
planned for organ preservation.  In most of the cases surgery is not possible due to extensive 
disease, inoperability of the disease condition, and poor general condition of the patient and 
associated comorbidities.  
 b) CHEMO IRRADIATION: 
Post-operative adjuvant chemo irradiation improved loco regional control and disease free 
survival in patients who had high risk features such as extra capsular extension and positive 
surgical margin (15,16).  Chemo radiation is emerging as the standard of care in locally 
advanced head and neck cancers. The meta analyses of chemo radiation reported by Pignon et al 
confirmed the benefit of chemo radiotherapy to be around 6 % (17). Induction chemotherapy 
followed by radiation showed similar survival rates and organ preservation in various trials (18–
20). The modest benefit of chemo radiotherapy is achieved with considerable morbidity. Chemo 
irradiation and induction chemotherapy will add to the morbidity in those patients with co 
morbidities, poor general condition, and poor renal function and also might not be possible to 
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administer this subset of patients.   The intent of treatment often becomes palliative when these 
patients are treated with radiotherapy alone.  There are different palliative radiotherapy treatment 
regimens described for locally advanced head and neck cancers  such as 30 Gy in 10 fractions,  
20 Gy in 5 fractions (21),  40 in 16 fractions (22), Quad shot regimen (14 Gy in 4 fractions) (23),  
etc depending on the institutional experience on toxicity rates and feasibility. 
Hyperthermia is an alternative modality which can be tried as this modality is proven to be 
beneficial in these locally advanced tumours where there is hypoxia and radio resistant clone of 
cells. Hyperthermia improves the effectiveness of radiotherapy and acts as a radiosensitizer (24). 
2.2) HYPERTHERMIA: 
Hyperthermia is defined as heating the tissues beyond the physiological temperature (42 degree 
Celsius to 45 degree Celsius).  
2.21) HISTORY: 
Hyperthermia is an ancient treatment described in literature which is as old as medicine.  The 
first paper on hyperthermia was published in 1886.  In 1898, Westermark, a Swedish 
gynecologist, published a paper describing marked regression of large tumours of the uterine 
cervix after local hyperthermia.  Interest in hyperthermia flourished in the 1970s and 1980s. The 
first international congress on hyperthermic oncology was held in Washington in 1975.  A 
Hyperthermia group was formed in 1981 in the United States and the European hyperthermia 
institute was formed in 1983. Hyperthermia research started in 1978 and the Japanese society of 
hyper thermic oncology was established in 1984.   
2.22. RATIONALE:   
The factors limiting the efficacy of loco regional control of cancerous cells are well known.  
These include the presence of hypoxic cells in the tumour mass, acidic environment, cells in the 
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radio resistant phase of the cell cycle (S and G1) and the potentially radio resistant type of cancer 
cells.  It has been proved that hyperthermia at 42 – 45 degree Celsius is lethal to the 
radioresistant hypoxic cells, cells at low pH and the radioresistant S phase cells. Hyperthermia 
causes direct cytotoxicity and radio sensitization.   
2.23) MECHANISM OF ACTION: 
The predominant molecular target for hyperthermic cell killing appears to be protein (25) . 
Protein denaturing and cell membrane damage is the most direct effect of hyperthermia toxicity 
(26).  Protein starts to denature when the temperature is greater than 40° C which leads to 
alterations in multi molecular structures (e.g. cytoskeleton and membrane) and enzyme activity.  
Nucleic acid damage is more likely to happen during the S phase of the cell cycle when the DNA 
is being synthesized and in the M phase of the cell cycle when chromosomes are dividing.  As a 
result cells die when they undergo mitosis. The newly synthesized DNA is vulnerable to heat 
stress, the double stranded DNA might be incorrectly joined or contain aberrant base pairs under 
heat stress. At the same time mutations can occur due to damaged DNA repair mechanisms 
under hyperthermia. Hyperthermia can decrease the DNA replication  process through  damage 
of key enzymes (27).  Hyperthermia can also damage the cell membranes which is a key concept 
in thermal chemo sensitization, as altered membrane may increase the permeability of drug 
uptake (28).  Hyperthermia affects many key functions of the cytoskeleton which is heat 
sensitive.  Heat stress can also lead to depolymerisation and inactivation of microtubule proteins 
and fragmentation of the mitotic spindle which will result in cytokinesis disruption  (29–31).  
2.24 HEAT SHOCK PROTEINS (HSP): 
If cells are exposed to heat, proteins of a defined molecular weight (mainly 70 or 90 k Daltons) 
are produced.  The appearance of these heat shock proteins tends to coincide with the 
development of thermo tolerance and their disappearance coincides with the decay of thermo 
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tolerance.  HSP are molecular chaperones (32). The function of a chaperone is to correctly 
assemble other macromolecules such as proteins and nucleosomes. When proteins and 
nucleosomes are synthesized chaperones attach to them and help them to fold to three 
dimensional conformations and perform their normal biological function. Chaperones themselves 
are not components of these macro molecules. When folding is complete the chaperones 
disassociate from the proteins. Hyperthermia can severely affect protein folding. Under heat 
stress, newly formed protein polypeptide chains tend to aggregate and lose their biological 
function.  HSP are actively involved in the protection of cells against heat damage. These heat 
shock protein localize to the cytoskeleton and help reinforce structural proteins and enhance their 
tertiary configuration following treatment with heat (33,34).  HSP also helps resist DNA 
fragmentation upon heating and decreases cell apoptosis  (35). The expression of HSP is 
temperature dependent.  Moderate hyperthermia stimulates HSP synthesis. In general it is widely 
accepted that HSP inhibits hyperthermic cell death, especially apoptosis (36–38). 
2.25 THERMOTOLERANCE: 
Cancer cells may confer thermotolerance as a result of continuous heat exposure or after pre 
hyperthermia treatment. Tumour tissues that develop thermotolerance are less susceptible to heat 
induced cytotoxicity. The development of thermotolerance depends on the temperature.  
Moderate hyperthermia has more chances to induce thermotolerance and 43 °Celsius seems to be 
a critical temperature (39).  Thermotolerance can develop rapidly by cooling down to 37° Celsius 
between two shock treatments. Thermotolerance is reversible if the cells are returned to normal 
temperature (28).  However thermotolerance takes much slower  than its induction and it is 
usually in 3 to 5 days in most cells (40,41). The development of thermotolerance is mainly due to 
the appearance of heat shock proteins(HSP expression) (33)(42). 
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2.26 HYPERTHERMIA INDUCED APOPTOSIS AND NECROSIS: 
Generally cells are committed to death through two distinct pathways: apoptosis and necrosis. 
Necrotic cell death is passive and involves lysis of the damaged cell and the release of its cellular 
contents to the surrounding environment (43).  Necrosis is a traumatic cell death and occurs 
when the injury to the cell is acute in nature followed by inflammatory response.  Apoptosis, in 
contrast, is an active and programmed cell death which involves condensation of the nuclear 
chromatin, shrinkage of the cytoplasm, blebbing of the membrane, nuclear fragmentation and 
finally the formation of apoptotic bodies (44).  Hyperthermia is capable of causing both necrosis 
and apoptosis depending on the temperature.  It was found that hyperthermia causes apoptosis at 
lower temperatures and necrosis at higher temperatures.   
2.27 HEAT AND TUMOR VASCULATURE: 
Additive toxicity in the tumour due to heat is due to the combination of inability of the blood 
vessels to undergo vasodilatation to the maximum extent and lesser dissipation of heat. 
Preferential heating and damage of tumor can be expected only if heat is preferentially delivered 
to the tumor or if heat dissipation by blood flow is slower in the tumors than in the surrounding 
normal tissues (45).  Tumour cells are found next to the endothelial cells along the thin walled 
tumour capillaries (46,47), which has sluggish blood flow (48,49).  As a result of sluggish blood 
flow and the decreased density of functional capillaries, the total blood flow per unit weight of 
tumours, particularly in larger tumours is smaller than that in most normal tissues (57,58).  
Consequently although blood flow may be greater in tumours compared with normal tissues at 
physiologic temperatures, the capacity of tumour blood flow to increase during heating appears 
to be rather limited in comparison with normal tissues due to inadequate vasodilatation (poorly 
formed vasculature and lack of proper nervous receptors). It is a well-known fact that  heat 
induces a prompt increase in blood flow accompanied by dilatation of vessels and an increase in 
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permeability of the vascular wall in normal tissues (52). Because the tumour blood vessels are 
unable to undergo vasodilatation to the maximum extent there is lesser dissipation of heat 
leading to temperature difference which is responsible for cytotoxicity. 
2.28 METHODS OF HYPERTHERMIA: 
In clinical applications, hyperthermia can be divided into three types: Local, regional and whole 
body hyperthermia. 
1) Local hyperthermia: Local hyperthermia is usually applied to a tumour while the surrounding 
normal tissue is not heated (53). Local hyperthermia can be applied by external or interstitial 
methods. 
a) External local hyperthermia: 
 External local hyperthermia is usually performed with superficial applicators such as 
radiofrequency, microwave or ultrasound.  Although the penetration depth can be tuned by the 
size or the frequency of the applicator, the therapeutic depth of   this type of hyperthermia is not 
more than 3 – 4 cm.  Tumour temperatures are increased and surrounding tissues are heated not 
to exceed tolerance levels (54).  Usually patients with chest wall recurrences, malignant 
melanoma lesions and lymph nodes of head and neck tumours are treated with external local 
hyperthermia. 
b) Intraluminal local hyperthermia: 
Intraluminal or endocavitary methods can be used to treat tumors within or near body cavities.  
Endocavitary antennas are inserted in the natural openings of hollow organs. These cavities 
include gastrointestinal (esophagus, rectum), gynaecological (vagina, cervix and uterus), 
genitourinary (prostate, bladder) and pulmonary (trachea, bronchus).  Localized treatment is 
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possible with various possible electrodes according to the size of the lesion and the size of the 
lumen. Sugimachi etal (55–57), Kitamura etal (58) and Saeki etal (59) have used intraluminal 
hyperthermia in addition to radiotherapy and chemotherapy to treat locally advanced esophageal 
cancers.   
 
c) Interstitial local hyperthermia: In order to treat deep seated tumours where external local 
hyperthermia is unreachable such as brain tumours, interstitial local hyperthermia can be applied 
(60).  There are several types of applicators for delivering energy by this method. Interstitial 
heating enables more heating of the malignant cells than the normal tissues when compared to 
other techniques. In this technique there is better control of heat distribution. Problems are 
difficulty of repeated invasiveness and limited sites of access. Interstitial thermo radiotherapy 
was tested against radiotherapy alone in  a prospective randomized study and did not show any 
additional benefit in spite of the efforts taken to deliver it (61). 
 
2) Regional hyperthermia: 
When a tumour is locally advanced or deep seated such as those in the abdomen and pelvis 
regional hyperthermia can be used. Unlike local hyperthermia in regional hyperthermia it is hard 
to avoid a temperature increase in normal tissues. Therefore it requires that heat dissipation in 
normal tissues is faster than in the tumour usually due to blood flow. Most clinical trials have 
used regional hyperthermia as an adjuvant to chemotherapy or radiotherapy, mostly in the pelvis 
when locally advanced or recurrent tumors are present (62). 
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a) Deep regional hyperthermia by external applicators: 
Treatments of deep seated tumours are difficult with electromagnetic (EM) energy since it can be 
absorbed by human tissue very quickly.  Therefore in order to deliver energy to the tumour while 
avoiding overheating adjacent normal tissue applicator arrays are used.  Annular phased array 
systems delivering electromagnetic energy and radiofrequency capacitive heating apparatus are 
examples of regional heating devices.  
b) Regional perfusion hyperthermia: 
Regional perfusion is a technique where heated fluids are used to perfuse cancerous tissue. It is 
usually used to treat cancers in the arms and legs like melanoma or soft tissue sarcoma where the 
cancer is in advanced stage or non resectable. When regional hyperthermia is applied to limbs 
and without a cytotoxic agent the temperature can be increased to around 43° C for as long as 2 
hours. However if a cytotoxic drug is applied simultaneously the temperature must be lower to 
avoid toxicities.   Clinically regional perfusion hyperthermia combined with chemotherapy has 
shown much higher response rate than treating cancer with systemic chemotherapy. The success 
is due to well controlled heat application and more drug concentrations possible. This success is 
due to both the homogeneous and well-controlled heat application and the much higher (more 
than tenfold) drug concentrations possible with this technique (62). However the procedure is 
more risky. 
3) Whole body hyperthermia (WBH): 
Whole body hyperthermia has been investigated since 1970’s as an adjuvant modality to 
chemotherapy or radiotherapy in metastatic disease. The temperature of WBH is usually limited 
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to 42 ° C because temperature higher than that can cause irreversible damage to brain and liver 
tissue. But this temperature can be maintained for hours. 
The application of WBH can be divided into three major types: thermal conduction, 
extracorporeal induction and radiant or electromagnetic induction. 
Thermal conduction can be achieved by immersion in heated fluids, heated air, heated blanket or 
using thermal chambers (similar to incubator).  
In extracorporeal induction blood is first pumped out of the patient’s body heated to 42°C and 
then put back into the body. 
Since the whole body temperature will be elevated it can be applied to patients only in good 
clinical condition, otherwise significant adverse effects will occur due to doubling of basal 
metabolic rate when compared to 37 degree Celsius. 
2.29) HYPERTHERMIA HEATING SYSTEMS: 
Hyperthermia has been achieved by external energy sources. Especially diathermic heating 
devices have become a new research focus in the treatment of cancer due to their targeting 
capability which eventually leads to accurate targeting capability and small side effects to 
healthy tissues (28). Most clinically used hyperthermia systems are diathermic, which means the 
heating of the body tissues due to their resistance to the passage of high frequency ultrasound 
waves, electromagnetic radiation and electric current. 
1) Ultrasound: 
The ultrasound induced hyperthermia effect is caused by tissue absorption of ultrasound waves at 
the frequency of 2   - 20 M Hz. Theoretically, ultrasound has the best combination of short 
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wavelengths among all the diathermic devices and therefore low attenuation coefficient which 
allows for deep penetration in the human body with the ability to focus power into small regions.  
With newly designed ultrasound hyperthermia delivery systems equipped with multiple 
applicators we have achieved improved heating uniformity and controlled depth of penetration. 
However in application, ultrasound has limited utility by the fact that it is incapable of 
penetrating air and bone (63,64). 
2) Electromagnetic fields: 
Electromagnetic field can cause temperature increase in biological tissues. According to the 
frequency EM field can be in the radiofrequency (RF) or micro wave range. Frequency between 
300 MHz and 300 G Hz are assigned to microwave. The most commonly used frequencies for 
microwave hyperthermia are 433, 915 and 2450 MHz. Frequencies higher than 2450 MHz have 
no value due to their limited penetrations.  Radiofrequency by definition occupies the band 
between 3 KHz and 300 GHz. 
In hyperthermia applications it generally means frequencies below microwave range usually 
between 10 – 120 MHz.  The radiofrequency frequencies of 13.56 and 27.12 have been widely 
used in hyperthermia. 
a) Radiofrequency: RF fields in the range of 10 – 120 MHz are used for treatment. A closed loop 
circuit is made which has a generator, a dispersive electrode (ground), patent and the needle 
electrode. The dispersive electrode and the needle electrode are active and the patient acts as a 
resistor. Due to the resistance of the tumor tissue the ionic agitation within the tumor tissue 
creates heating within the body. This can be tightly controlled through modulation of the amount 
of radiofrequency energy deposited.  
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b) Microwave: 
Microwave hyperthermia uses single wave guide microwave antennas at 434,915, 2450 MHz. 
The system has an antenna and non-contact temperature sensor which senses the temperature of 
the tissue and provides feedback that adjusts the microwave power increasing the tissue 
temperature. 
 
 
 
 
 
 
 
        
                                
 
  
 
 
 
Fig 1: Schematic diagram of the microwave 
waveguide     
Fig 2: Capacitive heating approach for heating 
tumors in the esophagus 
Fig 3: schematic diagram of single transducer 
ultrasound applicator for use in superficial tumours 
Courtesy (Fig 1,2 &3): Perez and Brady’s principles and practice of Radiation Oncology, 5th edition. 
Figure 4: Hyperthermia with radiofrequency radiative device. 
Courtesy: Thermal therapy – hyperthermia techniques – Critical reviews in Biomedical Engineering 
34(6): 491 – 542 (2006)  
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2.30) HYPERTHERMIA AND OTHER MODALITIES: 
Hyperthermia is used along with radiotherapy and chemotherapy, also used in increasing the 
perfusion of nano particle drugs, monoclonal antibodies and drug carrying polymers. 
2.31) THERMAL DOSIMETRY: 
Treatment outcome of hyperthermia is highly dose dependant.  The temperature of hyperthermia 
treatment and the exposure duration at that temperature could make a great difference in tumour 
growth. After examining numerous survival curves of different 
cell lines upon treatment, the threshold temperature for thermal 
damage was found. This threshold temperature is also called a 
breakpoint (65,66)  
 
The Arrhenius plot could be used to estimate the energy needed to inactivate the cells. The 
Arrhenius plot is typically biphasic which also suggests the existence of a breakpoint. The plot is 
steeper below the breakpoint than above it.  The calculated inactivation energy is around 120 – 
150 k cal /mole which is consistent with  the heat energy required to inactivate proteins and 
enzymes (67). Arrhenius plot is done by plotting the log of the slope of cell survival curves 
versus temperature. Above the breakpoint, a change in temperature of 10 C will double the rate of 
cell killing.  The rate of cell killing will drop by a rate of 4 to 8 for every drop in temperature of 
10 C.  The change in slope below the breakpoint is due to the development of thermotolerance 
during heating. 
  
Fig 5: Arrhenius plot Courtesy: Textbook of radiobiology for the radiobiologist Eric. J  
Hall 
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2.32) CUMULATIVE EQUIVALENT MINUTES (CEM 43) 
It has been demonstrated that hyperthermia cytotoxicity is dependent on both temperature and 
time, so that some time – integrated descriptor is the best concept of thermal dose. The quantity 
that has emerged as the most widely used measure of thermal dose is CEM43 degree Celsius CT 
90, the number of cumulative equivalent minutes at 43 degree Celsius exceeded by 90 % of the 
monitored points within the tumour.  Jones et al in his study (68) concluded that  hyperthermia 
with a thermal dose more than 10 CEM 43°C provides a benefit in local control when compared 
to a thermal dose of < 1 CEM 43 ° C. 
2.33) TEMPERATURE MEASUREMENT: 
Invasive thermometry was used initially in most of the clinical trials. Nowadays noninvasive 
thermometry is being studied. .Magnetic resonance imaging is more promising for monitoring 
and control of deep hyperthermia. The patient is taken into the MRI scanner during hyperthermia 
and proton resonance frequency shifts are measured as a means to determine temperature. MR 
thermal imaging has clearly demonstrated its usefulness for monitoring clinical hyperthermia 
(69). 
2.34) REVIEW OF CLINICAL TRIALS:  
1. Hyperthermia in addition to radiotherapy has shown local control and survival benefit. 
Vanderzee etal (70)  performed a prospective randomized control multicenter  trial (1990 – 96).  
The number of patients enrolled were 358 , who were diagnosed to have locally advanced pelvic 
tumours comprising of bladder cancer, rectal cancer, cervical cancers and were randomly 
assigned between radiotherapy versus radiotherapy and hyperthermia.  
 Hyperthermia was prescribed once weekly, 1 – 4 hours after radiotherapy to a total of five 
treatments. Treatment was continued till the measured temperature had reached 42° C and 
persisted for 60 minutes the maximum time not exceeding 90 minutes. In all these patients 
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comprising of pelvic tumours, the complete response rate was 39 %  in the control group and 55 
% in the study group who received radiotherapy and hyperthermia. The local control rates were 
more in the study group. The 3 year overall survival was 27 % in the study group and 51% in the 
combined group.  Among all the pelvic tumours, this combined treatment was found to be more 
beneficial in cervical cancers with the complete response rate was 83% versus 57%.  
Subcutaneous burns were observed in 20 patients, skin burns in 5 patients and deeper burns were 
noted in 2 of the patients. The acute and late radiation toxicities were similar between the two 
treatment groups.  
2.The Cochrane review (71) had reviewed six randomized controlled trials between 1987 and 
2009 for analysis (Chen  1997; Datta 1987; Harima 2001; Sharma 1991; van derZee 2000; 
Vasanthan 2005).  All these trials have randomized locally advanced cervix cancer patients 
between radiotherapy and radiotherapy with hyperthermia.  Combined treatment showed 
significant better outcome. The complete response rate was higher in the combined group 
(relative risk (RR) 0.56; 95% confidence interval (CI) 0.39 to 0.79; p < 0.001), with reduced 
local recurrence rates (hazard ratio (HR) 0.48; 95% CI 0.37 to 0.63; p < 0.001) and an improved 
overall survival (HR 0.67; 95% CI 0.45 to 0.99; p= 0.05) and a significantly better overall 
survival (OS) following the combined treatment (HR 0.67; 95% CI 0.45 to 0.99; p= 0.05).  There 
was no significant difference in the treatment related acute or late toxicities between the two 
treatment groups. 
3. A Cochrane review done on treatment with hyperthermia and radiotherapy had also 
demonstrated the benefit in rectal cancers (72). Six randomized controlled trials published 
between 1990 and 2007 were included in this review. Among them, four were single centre 
(Berdov 1990;  Berdov 1996; Kakehi 1990; Trotter 1996) and the remaining two (van der Zee 
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2000;You 1993) were multi centre trials.  The total number of patients were 520, 258 in the 
control arm and 262 in  the combined  arm.  The overall survival was better in the combined 
group (HR 2.06;95% CI 1.33-3.17; p=.001), at 2 years which did not persist at 3,4 and 5 years.  
A higher complete response rate was reported in the combined group. (RR 2.81; 95% CI 1.22-
6.45; p =0.01). Toxicity was reported only from two studies which had no differences between 
the two groups.  Late toxicity was not reported. 
4. Huigol etal, in a randomized study demonstrated benefit of hyperthermia and radiotherapy 
over radiotherapy alone in locally advanced head and neck cancers.  Fifty six patients were 
randomized into two groups, one  receiving radiotherapy and the other receiving radiotherapy 
and hyperthermia.  All the patients received 66 – 70 Gy.  Patients in the study group received 
additional hyperthermia which was delivered once a week on the same day of the week for five 
to seven sessions , with a radiofrequency machine operating at 8.2 MHz.  All the patients 
received precooling for ten minutes followed by hyperthermia for 30 minutes. Except for the 
thermal burns in the combined group, acute and late effects were comparable in both.  Complete 
response was seen in 42.4 % of patients in the study arm and   78.6 % in the patients in the 
combined arm. 
5.  Amichetti et al (73) in a phase 2 trial with 15 patients had tested microwave hyperthermia in 
cancers of unknown primary with N2 – N3 neck metastatic neck nodes. These 15 patients were 
treated with a median dose of 70 Gy and with hyperthermia  with  minimum temperature of 42.5 
degree Celsius and at a frequency of 280 – 300 MHz.  Hyperthermia was delivered twice a week 
20 – 25 minutes after radiation. Complete response was observed in nine patients (60%) and  
4(26 %) patients achieved a partial response and there was no response in the remaining patients. 
The overall response rates noted in the patients was 86.5 %.  The acute toxicities noted were 
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mild with dry desquamation. The reported cases of late skin toxicities were mild with 2 cases of 
soft tissue fibrosis.  Distant metastases was seen in 5 patients in  (1 patient with liver metastases, 
2 patients with lung and one patient with bone metastases). Nodal recurrence was noted 2 
patients, in one patient within the irradiated field after a duration of 20 months and in the other 
patient outside the irradiated field   after a duration of 25 months. Two patients died of non 
neoplastic unrelated causes (1 of cirrhosis and 1 of heart failure).  
6. Hyperthermia along with radiotherapy had increased local control in head and neck cancer 
patients with fixed, N3 neck nodes. Valdagni (74) et al had randomized 44 patients having head 
and cancers with N3 neck nodes to radical radiotherapy and radiotherapy with hyperthermia.  
The dose of radiotherapy was 64 – 70 Gy, in both the arms and hyperthermia was twice a week 
in the combined arm alone. There was significant difference in the response rate in the combined 
arm (p = 0.0152). The complete response rates were 82.3 % (14/17)   in   the combined arm and 
36.8% (7/19) in the radiotherapy only arm. The acute toxicities were similar in both the groups. 
Only one skin burn was observed in the combined arm. One patient in the combined arm died 
due to carotid rupture. The report of long term follow up of this randomized trial was published 
in 1993(75). The local control continued to be significant even after five years with a p value of 
0.0164.  Complete response was seen in 9/22 patients in the radiotherapy alone arm and 15/18 
patients  in the combined arm.   The 5 year survival was more in the combined arm (53.3 % Vs 
0%). Late toxicity occurred in the form of bone necrosis in two patients who had mandibular 
bone fixation in the combined arm. 
7. Hyperthermia as a combined modality has shown better control in those patients with 
advanced disease when compared to those patients having early cancers.  Datta et al in a 
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randomized clinical study (76) had treated the study group with hyperthermia and radiotherapy 
and the control group with radiotherapy alone. The patients received 60 – 75 Gy fraction with 
conventional fractionation. Hyperthermia was carried out with radiofrequency waves at 27.12 
MHz using a diathermy machine twice a week until a temperature of 42.5 – 43 degree Celsius, 
was reached with a gap of 72 hours between two sittings.  The patients received radiotherapy 
immediately following hyperthermia. The complete response in stage 3 disease was 20 % in the 
control group   and 58 % in the study group.  In stage 4 patients, 38%   had complete response in 
the study group versus 7 % in the control group.  Pain was well controlled in the study group 
patients (79 % versus 50%) when compared to control group. It was noticed that regression rates 
were better in those lesions with larger dimensions.  The acute toxicity rates were almost similar. 
Erythema and facial edema were seen in three out of thirty three patients in the study group.   
8.Martine Franckena (77) in a review article on hyperthermia and radiotherapy had concluded 
that hyperthermia when added to radiotherapy definitely improves local control and offers 
survival benefit in locally advanced cervical cancers.  It was also insisted in this article that 
modern technology and the appropriate methodology should be used in clinical practice in terms 
of delivery devices, temperature measurements and quality assurance. 
9. There are studies which did not show much benefit with hyperthermia. In a multi institutional,  
prospective randomized study which had two groups of patients of locally advanced carcinoma 
cervix treated with radiotherapy versus radiotherapy and hyperthermia (78),  all patients received 
external beam radiotherapy and brachytherapy. The study group received five sessions of 
hyperthermia with a radiofrequency capacitive device. There was no significant difference 
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between the two arms in terms of local control and survival .The acute toxicity was more in the 
study group (18.2% Vs 3.6%) with no difference in the late toxicity.  
10. Hyperthermia along with chemoradiotherapy has also demonstrated benefit in head and neck 
cancers.  Huilgol etal (79)  treated 40 patients with chemoradiation along with hyperthermia. All 
patients received 70 Gy in conventional fractionation with weekly chemotherapy of Cisplatin (50 
mg) or paclitaxel (60 mg).  They all received hyperthermia on a radiofrequency machine at 8.2 
MHz for thirty minutes at 41° C to 43 ° C with pre cooling of 10 minutes to 5 °C.  There were no 
enhanced mucosal or thermal toxicities when documented to their earlier experience with chemo 
irradiation. The overall survival was 75.69 % at 1 year and 63.08 % at 2 years.  
11. Hyperthermia has also been tested and proven to be beneficial in patients with recurrent 
superficial breast tumors who were already treated with radiotherapy. Vernon etal (80) had 
combined five phase 3 trials (1988 -1991) which had 306 patients who were randomized between 
hyperthermia and hyperthermia with radiotherapy. The overall local response was better in the 
combined  arm  (59%) when compared to the radiotherapy arm alone (41%).  
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3. METHODS AND   MATERIALS 
3.11. TITLE OF RESEARCH PROJECT:  
A Pilot study to evaluate the feasibility, tolerance and efficacy of addition of hyperthermia to 
external beam radiotherapy (EBRT) on patients with locally advanced non metastatic inoperable 
head and neck cancer for palliation of symptoms. 
3.12. TYPE OF STUDY:This study was a single arm prospective study.  The study was conducted 
after approval by the Institutional Review Board (Ethics committee) on 04.01.2013.  The study 
included patients who fulfilled the inclusion  criteria and were registered in the department of 
radiotherapy unit 2, Christian Medical college between January 2012 to August 2013.   All 
patients were informed about the treatment protocol and written informed consent was obtained 
from the patients to participate in the study. 
3.13 TARGET SAMPLE SIZE AND RATIONALE:  Since it is a pilot study the sample size was 
conveniently selected to be 20 patients to assess the feasibility. 
3.14. FUNDING: This study was funded by the FLUID research grant. 
3.15. OBJECTIVES OF THE STUDY: 
a) Primary objectives:  
1. To assess the feasibility and toxicity of hyperthermia along with radiation in patients with 
locally advanced non metastatic head and neck cancers 
2. To assess the palliation of distressing symptoms in locally advanced head and neck cancers 
treated with palliative intent 
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b) Secondary Objectives: 
1. To assess   the efficacy of this modality in terms of disease response as weekly clinical 
assessment, at the end of treatment and at three months 
3.16. INTERVENTION AND COMPARATOR AGENT – The interventions are radiotherapy and 
Hyperthermia in a single group of patients. Comparator agents do not exist in this study 
This cohort was compared with   age and stage matched control of 40 patients treated with 
palliative radiotherapy regimens. Comparison was done between  the patients treated with 
hyperthermia in this study, ten patients treated with 66 Gy in 33 fractions (conventional 
fractionation along with concurrent chemotherapy), data from the study published on 33 patients 
who were treated  with 40 Gy in 10 fractions and data from the study done on 10 patients treated 
with 6/7 fractionation.  The toxicity profile, tolerability, response rates, local control and time to 
progression (local/systemic) were compared. 
 3.17. PRETREATMENT WORKUP: 
All the patients were evaluated by physical examination and required laboratory investigations, 
radiological investigations which included complete blood picture, liver function tests, 
creatinine, chest x ray, baseline CT head and neck.  
Flexible naso pharyngo Laryngoscopy (NPL scopy) was done for assessment of the extent of the 
primary disease and staging before initiation of treatment.  Biopsy from the tumour or FNAC 
from the nodes were done. ECG and ECHO for baseline evaluation of cardiac function were 
done. All patients had routine dental assessment and clearance before initiation of radiotherapy. 
All the patients had dietary consultation before and during the treatment. 
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3.18 .KEY CRITERIA: 
The patients who were diagnosed to have inoperable locally advanced head and neck cancers 
(stage IV A and IV B) who were unfit for chemotherapy and decided for palliative treatment 
were screened for inclusion into the trial 
 
a. Inclusion criteria: 
a) Performance status - </ = 2 
b) More than 18 years of age and not more than 75  
c) Non metastatic histologically or cytologically proven squamous cell carcinoma of the 
following sites: 
                      1. Oral cavity  
                      2. Larynx 
                     3. Hypopharynx 
                    4. Carcinoma unknown primary with neck nodes 
d) Inoperable disease – intent of treatment being palliative 
e) Not fit for chemotherapy due to poor general condition or renal condition 
 
b. Exclusion criteria: 
a) Metastatic disease 
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b) Patients undergoing altered fractionation schedules (400 TD/6 fractions per week) 
c) Patients who had prior treatment with chemotherapy 
d) History of cardio logical interventions viz. CABG, PTCA, temporary or permanent pacing 
e) Unstable angina 
f) acute myocardial infarction within last 6 months 
g) Any implanted device insitu 
h) Patients with leprosy or syringomelia or syringobulbia or any other medical or surgical 
condition in which there is impaired pain perception 
i) Heart rate > 90 bpm 
j) Hypertension : Diastolic > 100 mm Hg and /or systolic < 90 mm Hg 
K) Hypotension : Diastolic < 50 mm Hg and / or systolic < 90 mm Hg 
l) Severe cerebrovascular disease: multiple cerebrovascular accidents (CVA) or a CVA < 6 
months before treatment 
 
 
 
 
35 
 
3.19. SCHEMATIC DIAGRAM OF THE PROTOCOL: 
Screening of the patient 
 
Assesment + clinical + NPL scopy + EORTC QOL H & N assessment (self administered 
questionnaire for baseline quality of life) + imaging (CT scan) (Dental clearance and dietary 
consultation) 
Radiotherapy as per protocol – Cobalt 60 beam/ 66 Gy to the CTV primary 5 days a week once 
daily with a TD of 200 cGy per fraction 
Hyperthermia once in a week on a particular day – 30 minutes before radiotherapy 
Weekly clincal assesment of the radiation reactions       
 
End of RT assessment – Clinical  + NPL scopy + EORTC H & N assessment (self administered 
questionnaire)      
 
Assesment at the end of six weeks after radiotherapy clinically, with NPL scopy and EORTC 
QOL H & N assessment (self administered questionnaire)                     
 
Three months from the date of completion of radiotherapy – assessment – clinical, NPL scopy, 
EORTC QOL H&N assessment (self administered questionnaire) and imaging (CT scan)   
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3.20. OUTCOMES:    
a) Primary outcomes: 
1. To assess the feasibility, clinical utility of hyperthermia concurrently with palliative 
radiotherapy for head and neck cancers. Feasibility was assessed in terms of technical issues, the 
amount of break(discontinuation) in treatment due to toxicity and total duration required to 
complete the complete course of radiotherapy 
2.To assess the tolerability of use of hyperthermia concurrently with palliative radiotherapy for 
head and neck malignancy in terms of incidence and severity of radiation related toxicities like 
dermatological toxicity, mucositis, hematological toxicity graded by common toxicity criteria 
b) Secondary Outcomes: 
1. To assess the efficacy in terms of disease response at the end of radiotherapy by clinical 
examination at the end of six weeks and at three months by CT scan with RECIST criteria 
2.To assess the improvement of quality of life at the end of radiotherapy and at 6 weeks and 3 
months from the completion of radiotherapy by EORTC(H&N) QOL assessment questionnaire 
3.21 TREATMENT: 
a) RADIOTHERAPY: 
Simulation was done with the patient in supine position with immobilization  with a 
thermoplastic mask. Then planning was done in the simulator. Radiotherapy was delivered with 
cobalt 60 photons. Three field technique with two parallel opposed fields and 1 anterior neck 
field was used. The two parallel opposed fields were designed so as to fit the primary and the 
nodes with a margin. Anterior field was used to treat the nodes. Spine shielding was done at 40 
Gy and the posterior neck was treated with electrons. Boost plan was done at 50 Gy in which the 
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borders of the photon field were shrinked and the remaining dose was delivered.  After planning 
the radiotherapy charts were sent for calculation which was carried out in the treatment planning 
system and then treatment was initiated. The distribution and the dosimetry were reviewed by a 
senior consultant and a medical physicist. 
 Radiotherapy dose: 
Phase I :  Total dose of 50 Gy (2 Gy per fraction) was delivered through the lateral portal which 
encompassed the primary and the nodes with a margin and the possible sites of microscopic 
spread. 
Phase II: Field size reduction was done at 50 Gy and 16 Gy was delivered to the radiotherapy 
portal encompassing the primary and the significant nodes with a margin. 
The areas not needed to be treated were shielded by manual lead wires, which were represented 
on the simulator film and reproduced in the treatment machine.  
Change of match was done at every 22 Gy. 
Spine shielding was done at 40 Gy and the posterior neck was treated with electrons.  
b) HYPERTHERMIA: 
The patients were treated with hyperthermia once a week for 30 minutes just before radiotherapy 
on the same particular day. Hyperthermia was delivered by galvotherm 500 W machine ( Gemi 
manufacturers). Patients were seated in a chair with the paddles focused towards the region of 
treatment. The paddles were kept as close to the patient’s body but not in contact with the 
surface. The active paddle was kept on the side of the neck which required more temperature and 
the passive paddle on the opposite side. After positioning the patient the power button was  
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Pic 1 : Hyperthermia machine and paddles                                   Pic 2 : Contactless infrared thermometer 
                                           
 
Fig 3: Picture showing hyperthermia settings 
 
 
 
 
Paddle 
Power settings 
Timer Tuning 
settingss 
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switched on and the frequency and the current was adjusted  and treatment was started after the 
timer was set at 30 minutes. Temperature was monitored by an infrared thermometer every 10 
minutes for 30 minutes and was noted down in the record. Care was taken that the temperature 
did not exceed 102ºF. The frequency was at 27 MHz and the current was set at 4 mA. After 
completion of hyperthermia the patient was treated with radiotherapy. Six sittings were delivered 
once a week throughout the treatment. 
3.22. WEEKLY ASSESMENT AND FOLLOW UP: 
Patients were assessed weekly for tolerance of treatment and acute toxicity documented by 
RTOG and CTCAE criteria.  Radiation dermatitis and mucositis was graded according to the 
RTOG criteria (Appendix 6). Hematological parameters (Haemoglobin, Total counts, differential 
counts and platelets) were monitored and were graded according to the CTCAE 
criteria(Appendix 7)  if there was any abnormality. The nodal size was measured and recorded 
every week. Neck separation was also measured and noted   and repeat calculation was done if 
there was any gross variation. 
All patients underwent an End RT assessment with bloods, NPL scopy,  chest xray were done. 
All patients were followed for six weeks   and then after three months. Each visit bloods, ENT 
examination and chest x ray were done. Additionally a CT scan was done after three months for 
disease response assessment. 
3.23) RESPONSE ASSESMENT: 
Response assessment was done by RECIST criteria (Appendix 8) 
Date of enrolment: The first patient was enrolled in January 2013(08/01/2013) and the tenth 
patient in August 2013(23/08/2013). 
40 
 
3.24) TRIAL BENEFITS: The study patients were covered under the institutional insurance 
scheme for the costs of any trial related complications and hospitalization. 
3.25) STATISTICAL ANALYSES: For the primary outcome (Categorical variable) descriptive 
statistics are applied and frequency distributions are plotted. As per CTCAE criteria, toxicity was 
graded (Categorical variable) and descriptive statistics are applied and frequency distributions 
are plotted. 
European Organization for research and treatment of cancer Quality of life (EORTC H QOL H 
& N)(Appendix 9) quality of life tool which is a validated and accepted QOL tool for head and 
neck cancer was administered before starting radiotherapy and at the completion of radiotherapy 
and at follow up. Mean value before and after treatment was compared and test of significance 
was done (paired t –test) 
Response was compared with CT scans based on pre and post treatment tumor volume 
(Wilcoxan sign test). 
Survival analysis was done by Kaplan meier survival analysis. 
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4. RESULTS 
A total of ten patients were included in the study during the period of   January 2013 to August 
2013.  All the patients were planned for   hyperthermia and radiotherapy as per the study 
protocol.  Six patients underwent treatment as per the protocol and among the remaining four, 
one patient discontinued treatment and the rest of them died due to complications while on 
treatment. The data of these patients who completed the planned treatment was analyzed for 
response   and toxicity during follow up. The demographic characteristics and evaluation of 
toxicity during therapy was done for all ten patients. 
4.1 PATIENT CHARACTERISITICS:      
4.11 AGE and SEX: Mean age of the patients (n = 10) was 57.4 years and range was 33 – 71 
years. Majority of the patients were in the age group of 61 to 70 years.  
  
 
All the patients were male patients. 
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Fig 5: Age distribution of patients and corresponding percentage values 
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4.12 SOCIOECONOMIC STATUS: 
Kuppuswamy’s  classification was used for the stratification of socioeconomic classification 
(81).  Among the ten patients,   one   belonged to upper middle class, four to lower middle class,   
one to upper   lower class  and four   to lower class. 
4.13 PERFORMANCE STATUS:  
Five patients had a performance score of ECOG 1 and the remaining five patients had a 
performance score of ECOG 2. 
4.14 SITE OF TUMOUR: 
The most commonest   site  of  tumour  was pyriform sinus followed by tongue. 
4.15 PRESENTING SYMPTOMS: 
The commonest presenting symptom was neck swelling (30 %). The other presenting symptoms 
were pain (26%) which included throat pain, pain in the region of   neck swelling,  painful  
ulcerative lesions and referred pain in the ear, dysphagia (20 %) ,  hoarseness of voice (12 % ) of 
and tongue ulcer (12 % ). 
4.16 ADDICTIONS: 
Among the 10 patients, 7 patients were addicted to smoking, 4 patients to tobacco consumption 
in the form of leaves and along with betel nut and 2 patients to alcohol consumption.  Two 
patients were addicted to a combination of smoking and tobacco and 2 patients to a combination 
of tobacco and alcohol consumption.         
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Fig 6 – Graphical representation of distribution of the site of tumour 
Fig 7 :  No of patients  addicted to smoking, alcohol consumption and tobacco chewing  
Abbreviations: S = smoking, T = Tobacco chewing, A = alcohol consumption, S + T = smoking and 
tobacco consumption, T + A = Tobacco chewing and alcohol consumption 
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4.2 TUMOUR CHARACTERISTICS: 
4.21 T STAGE : 
Among the 10 patients, 3 patients (30 %) had T4b stage with infiltration of the pre vertebral and 
retropharyngeal spaces and encasement of the carotid vessels, among which two patients had 
primary arising from the  hypopharynx and one from lateral border of the tongue. 
Three patients (30 %)   had T4a stage, 2 patients with  hypopharyngeal  primaries with the 
tumour infiltrating the cartilages and the other patient had a tongue primary  infiltrating the 
intrinsic muscles. 
One patient (10%) had T3 stage with primary in the base of the tongue and 2 patients (20 %)   
had   T 2 stage  with primary arising from the pyriform sinus.  
Table 1 : Distribution of  T stage and their percentage 
T stage No of patients Percent(%) 
Tx 1 10 
T2 2 20 
T3 1 10 
T4a 3 30 
T4b 3 30 
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4.22 N STAGE 
N2b nodal status was present in 6 patients (60 %) of patients and   N3 nodal status was present in 
3 patients (30 %).   The remaining one  patient (10%) had N2c nodal status. 
Table 2: Distribution of   N stage and their percentage 
N STAGE No of patients Percent(%) 
 
N1 0 0 
N2a 0 0 
N2b 6 60 
N2c 1 10 
N3 3 30 
 
 
 
  Fig 9 : 33 year old gentleman, case of 
locally advanced hypopharynx. The 
growth is seen infiltrating the pre 
vertebral space. 
Fig 8: 45 year old  gentleman  case of locally 
advanced carcinoma Tongue. The tumour is 
seen encasing the right carotid vessel 
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Fig 10:  A 62 year old gentleman diagnosed t have Unknown primary with a N3 neck node   measuring about 9 x 8 
x 10 cm in dimensions involving Level 1b, 2 , 3 ,4 levels on right side 
Fig 11:  A 71 year old gentleman diagnosed to have locally 
advanced carcinoma Tongue. Figure shows bilateral necrotic nodes 
involving predominantly level 2 and 3 
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4.23 STAGE GROUPING 
Table 3:   Stage grouping of the patients 
STAGE FREQUENCY PERCENT(%) 
Stage 4a 4 40 
Stage 4b 6 60 
 
4.24 HISTOLOGY: 
The histology was as poorly differentiated squamous cell carcinoma in 5 patients,  moderately 
differentiated squamous cell carcinoma in 4 patients and  well differentiated squamous cell 
carcinoma in 1 patient. 
 
 
4.3 TREATMENT CHARACTERISTICS: 
The treatment planned for the patients was radiotherapy, five days a week along with six once 
weekly hyperthermia treatment.  The radiotherapy dose planned was 66 Gy in 33 fractions with 
conventional technique using Cobalt 60 machine.   
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Fig 12 : Pictorial representation of different histologies.   
Abbreviations: PDSCC – poorly differentiated squamous cell 
carcinoma, WDSCC – well differentiated squamous cell 
carcinoma, MDSCC – moderately differentiated squamous cell 
carcinoma 
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Table 4:  Combined treatment details of the patients: 
Pt No RT Dose(Gy) Hyperthermia  Duration of 
treatment 
Reason of deviation 
from 
treatment 
1 66  6 9 weeks Nil 
2 14  2 7 days Death* 
3 66  6 6 1/2weeks Nil 
4 66                              6 6 1/2 weeks Nil 
5 6 1 3 days Discontinued * 
6 66 6 61/2 weeks Nil 
7 56 5 8 weeks Death* 
8 36 1 4 weeks Death* 
9 66 6 9 weeks Nil 
10 66 6 8 weeks Nil 
Discontinuation and Death*   = details are explained below in section 4.35 & 4.43 
4.31 RADIATION THERAPY: 
 Among the 10 patients 60 % (6 patients)   received the planned dose of 66 Gy of radiation .  One 
patient discontinued treatment after 8 Gy  (4 fractions) due to personal reasons.  The remaining   
3 patients could not continue the planned treatment due to life threatening complications which 
lead to  death .  Among the three who died,  one patient received 56 Gy,  the second and the third 
patients received 36 Gy and 14 Gy respectively. 
  
Fig 13: Simulator film of a 70 year old gentleman who was diagnosed to have 
Carcinoma hypopharynx T2N2bM0.  The node was outlined with lead wire 
during simulation. 
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4.32 HYPERTHERMIA TREATMENT: 
Among the 10 patients, 6 patients(60 %)  received the planned six sittings of hyperthermia, 1 
patient (10 %) received 5 sittings, 1 patient(10 %) received 4 sittings and  2 patients(20 %)  
received only 1sitting of hyperthermia 
4.33 MEAN TEMPERATURE READINGS:   
The mean temperature reading measured with the contactless infrared thermometer in patients 
was 101.4 ° F. Three   readings were measured during each treatment of  hyperthermia and the 
mean of those readings was taken. The mean temperature was 101° F in seven patients and 102° 
F in three patients. 
4.34 DURATION IN WEEKS AND TREATMENT COMPLETION: 
  Among the 10 patients 3 (30 %) completed the treatment within the planned duration of 6 ½ 
weeks,   3 (30%) had delay in treatment   (2 completed in 9 weeks and 1 in 8 weeks) and 4 (40%) 
did not complete the planned treatment.  (refer table 4). 
4.35 TREATMENT BREAKS AND REASONS AND DISCONTINUATION: 
Three patients completed treatment within  6 ½  without any breaks, 1 patient had 3 fractions and 
discontinued treatment due to social reasons and 2 patients died after undergoing 7 and 18 
fractions of radiotherapy.   Among the remaining four patients, 1 patient had one break of 9 days 
due to grade 3 dermatitis, the other 3 had two breaks each  due to grade 3 mucositis,  grade 4 
mucositis,  grade 3 dermatitis or tumour bleed.  The longest duration of   break in radiotherapy 
was 20 days in a patient who had two breaks, one for 15 days and the second for 5 days.  
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Table 5 : Duration and reasons of treatment breaks 
Pt No No of  
breaks 
Duration of each 
break in days 
Reason Comment 
1 2 7 each Gr 3 & Gr 4 mucositis - 
2           - - - Death after 14 Gy  
3 Nil Nil Nil - 
4 Nil Nil Nil - 
5 - - - Discontinued after 6 Gy 3 
fractions(social reasons) 
6 Nil Nil Nil - 
7 2 2 & 6  Tumour bleed and 
grade 3 mucositis 
Death at 56 Gy 
8 - - - Death at 36 Gy 
9 2 14 & 5  Grade 3 mucositis & 
Grade 3 dermatitis 
- 
10 1 9 Grade 3 dermatitis - 
The major reason for treatment break was Grade 3 mucositis (42%), followed by grade 3 
dermatitis (28%).  The other reasons were Grade 4 mucositis (14%) and tumour bleed (14%).  
4.4 TREATMENT ASSOCIATED MORBIDITIES: 
4.41 NON HAEMATOLOGICAL TOXICITY: 
Weekly assesment was done for all patients to monitor   the   toxicities.  CTCAE criteria were 
used to grade toxicities like cough, throat pain, dysphagia, anorexia, fatigue.  RTOG scale was 
used to assess dermatitis and mucositis.  Pain was assessed with Universal pain assessment tool.  
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a) DERMATITIS: 
Table 6:  Table representing the number of patients who had various grades of dermatitis during 
treatment 
Weeks of 
treatment 
Grade 1 
dermatitis 
Grade 2 dermatitis Grade 3 dermatitis Grade 4 dermatitis 
First week 1    
second 4  2   
Third 6 3   
Fourth 2 6 1  
fifth 2 5 1  
Sixth  6 1  
Seventh  6   
Three patients had grade 3 dermatitis which occurred in the fourth, fifth and sixth weeks leading 
to treatment breaks.  
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Fig 14 – Graphical representation of dermatitis in patients during treatment in weeks 
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b) MUCOSITIS: 
Table 7 : Table representing the number of patients who had various grades of mucositis during 
treatment 
Weeks in 
treatment 
Grade 1 Grade 2 Grade 3 Grade 4 
First week 2 3   
Second week 4 1   
Third week 4 3 1  
Fourth week 3 2 2 1 
Fifth week 2 5   
Sixth week  5  1 
Seventh week  5   
Two patients had grade 3 mucositis in the third and fourth week. Two patients had grade 4 
mucositis in the fourth and sixth week. 
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Fig 15: Graphical representation of all grades of mucositis in patients during treatment. 
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C) PAIN ASSESSMENT: 
Pain was assessed every week according to the pain score and analgesics were administered and 
adjusted according to the WHO step ladder pattern. 
Table 8: Table representing the different pain scores  during treatment 
Weeks in 
treatment 
Pain score 
Mild 
Pain score 
Moderate 
(interfere with 
tasks) 
Pain score 
moderate 
(interfere with 
concentration) 
Pain score 
moderate 
(interfere with 
basic needs) 
Pain severe 
( needs bed 
rest) 
First week 8 2    
Second week 9     
Third week 4 4    
Fourth week 3  2 2  
Fifth week 2 4  1  
Sixth week 1 4  1  
Seventh week 2 3    
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Fig 16: Graphical representation of the maximum pain scores experienced by all the patients 
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Mild pain (score2) was experienced by 55 % of the patients,  32 % of patients had moderate pain 
interfering with tasks(score 4), 3.8 % of patients had moderate pain interfering with 
concentration (score 6), 7.6 % of patients had moderate pain interfering  with  basic  needs(score 
8). Pain was well controlled with combination of NSAIDs, weak opioids (Tramadol) and 
adjuvant analgesics (amitriptyline). 
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D) THROAT PAIN: 
Grade 3 throat pain occurred in the fifth, sixth and seventh weeks. None of the patients had grade 
4 throat pain . 
Table 9 : Table representing the number of patients who had various grades of throat pain   during 
the treatment 
Weeks in 
treatment 
Grade 1 
Throat pain 
Grade 2 throat 
pain 
Grade 3 throat 
pain 
Grade 4 throat 
pain 
First week 2 3   
Second week 4 4   
Third week 2 5 1  
Fourth week 1 4 2  
Fifth week 1 5 1  
Sixth week  3 3  
Seventh week  3 3  
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Fig 17: Graphical representation of all grades of throat pain in patients during treatment 
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E) DYSPHAGIA: 
Majority of the patients (65 %) had grade 2 dysphagia.   Grade 3 dysphagia occurred in 17%  of 
the patients during the fourth, fifth, sixth and seventh week and all these patients needed ryles 
tube insertion for feeding purpose. 
Table 10: Table representing the number of patients who had various grades of dysphagia during treatment 
Weeks in 
treatment 
Grade 
1 
 
Grade 
2  
Grade  
3  
Grade 
4  
1st week 1 3   
2nd week 3 4   
3rd week 1 5   
4th week 1 4 2  
5th week 1 4 1  
6th week  4 2  
7th week  2 2  
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Fig 18: Graphical representation of all grades of dysphagia in patients during treatment starting from week 1 to week 
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g) COUGH: 
Grade 3 cough was experienced in fourth, fifth, sixth and seventh weeks. 
Table 11: Table representing the number of patients who had various grades of cough  during the 
treatment 
Weeks in 
treatment 
Grade 1 
cough 
Grade 2 cough Grade 3 cough 
First week 3 1  
Second week  2  
Third week  5  
Fourth week 1 3 2 
Fifth week 1 3 2 
Sixth week 1 4 1 
Seventh week  3 1 
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Fig 19: Graphical representation of all grades of cough in patients during treatment starting from week 1 to week 7 
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H. ANOREXIA AND FATIGUE: 
One patient experienced grade 3 anorexia in the sixth week of treatment. Majority of the patients 
had grade 2  fatigue in the last two weeks of treatment. 
I ) NAUSEA AND VOMITING: 
Only 2 patients had grade 3 nausea, the remaining had grade 2 nausea. None of the patients had 
grade 3 vomiting. 
J) RYLES TUBE PLACEMENT: 
During the treatment 50 % of the patients had ryles tube placement. Two patients had   before 
treatment and the remaining during treatment. Two patients refused ryles tube feeding in spite of 
requirement. 
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4.42)HAEMATOLOGICAL TOXICITY: 
Hemoglobin was monitored once a week during treatment.  One patient had grade 1(9.9 gm%) 
anemia for which he was started on hematinics after which his hemoglobin level had improved 
(10.5 gm%).  Three patients received one unit of blood transfusion each. Among them, two 
patients had grade 2 anemia (8.8% gm%, 9.5 gm%) which had improved to grade 1(10.6 gm%, 
11.8 gm%) after blood transfusion. The third patient had grade 3 anemia (7.9 gm%) which had 
improved to grade 2 anemia (9.5% gm%) after blood transfusion . 
 
 
 
 
Total white blood cell counts, their differentials and platelet counts were monitored each week. 
None of the patients had low total counts , differential count and low platelet counts. 
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Fig 20:  Mean haemoglobin values of all the patients represented from week 1 to week 7 
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4.43)  DEATH: 
Three patients died after initiation of treatment. 
PATIENT 1: 
The first patient died after completion of 14 Gy. He was diagnosed to have carcinoma 
hypopharynx stage T4aN2cM0. He had stridor after 7 fractions  ,underwent an emergency 
tracheostomy and was hospitalized. After discharge from ward, he presented to subsequent OPD  
with complaints of fever, cough and generalized weakness. He was diagnosed to have right lower 
zone pneumonia and was admitted and treated with antibiotics. His general condition did not 
improve, and he had progressive disease. In view of this he was advised  supportive care at 
home. He died later at home which was informed by the relatives.  
PATIENT 2: 
This patient  died after completion of 36 Gy.  He was diagnosed to have carcinoma hypopharynx 
stage e T4bN3M0.  He had sudden onset of breathlessness and died suddenly at home which was 
informed by the relatives. 
PATIENT 3: 
This patient   died after completion of  56 Gy.  He was diagnosed to have carcinoma tongue 
T4bN2bM0.  He presented with complaints of cough, breathlessness and chest x ray showed 
multiple bilateral reticular opacities.  He was diagnosed to have bilateral pneumonia, was 
hospitalized and was treated with antibiotics and other supportive measures.  His general 
condition did not improve and he died of respiratory failure. 
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4.5 RESPONSE EVALUATION AT SIX WEEKS: 
The data of six patients was available for response evaluation at the end of six weeks. 
4.51 NODAL RESPONSE: The clinically palpable nodes were measured each week during 
treatment and during follow up.  During the first follow up there was 56.25% reduction in nodal 
size in the first patient,   33 % reduction in the second patient , 75 % reduction in the third  
patient and more than 85 % of reduction in the remaining three patients.  The mean reduction in 
the nodal size was 70 % at first follow up. 
4.52 RESPONSE OF THE PRIMARY LESION:  
The primary site was assessed by clinical examination or NPL scopy at the end of six weeks.  
One patient was a case of unknown primary, among the remaining   five patients, 2 patients did 
not have disease at the primary site, 2 patients had residual disease and 1 patient had progression 
of the disease. Overall,   four patients had disease regression and two patients had progressive 
disease, one at the primary site and the second had lung metastases even though there was 
regression at the nodal site  
4.53 DISTANT METASTASES: 
One patient had distant metastases (lung) at first follow up (6 weeks). 
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Table 12 : Response assessment at six weeks: 
Patients Primary Node  Distant Comments 
Pt 1 Unknown primary 85 % reduction in 
size 
No metastases Disease 
regression 
Pt 2 Residual present 56 % reduction in 
size 
Lung metastases Disease 
progression 
Pt 3 No disease 33 % reduction in 
size 
No metastases Disease 
regression 
Pt 4 No disease 85 % reduction in 
size 
No metastases Disease 
regression 
Pt 5 Progressive disease 87.5 % reduction  No metastases Disease 
progression 
Pt 6 Residual present 76 % reduction  No metastases Disease 
regression 
4.6   RESPONSE EVALUATION AT THREE MONTHS: 
One patient died eight weeks after treatment and five patients had come for follow up at three 
months. Four patients had disease progression and one patient had complete response.  
Table 13: Response assessment at three months: 
Abbreviations: CR: complete response, PD: progressive disease 
 
Patients Primary site Nodal size in 
comparison with first 
follow up 
Distant Comment 
Pt 1 Unknown primary Increase in size Lung metastases PD 
Pt 2 Residual present Same size  Lung and liver 
metastases 
PD 
Pt 3 Residual present(not 
seen at first follow 
up 
Same size  No metastases PD 
Pt 4 No disease No clinically palpable 
nodes 
No metastases CR 
Pt 5 Progressive disease Same size  No metastases PD 
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CT scans done post treatment showed decrease in the nodal size which was statistically 
significant. 
Table 14: Comparison of pre-treatment and post treatment CT scans 
Pt .No CT pre RT 
Primary(cm)  
CT post RT 
primary(cm) 
 
CT pre RT 
node(cm) 
CT post RT 
node(cm) 
1 - - 76 26 
2 6 0 12 0 
3 28 46.4 10.44 1.92 
4 10.5 5 8.7 5.28 
5 5.06 5.5 33.12 32 
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Fig 21: 70 year old gentleman diagnosed to have carcinoma pyriform sinus and left sided left sided level 2 neck node measuring 
3 x 3.9 cm. Post treatment the patient has complete response with minimal thickening at the left sided pyriform sinus and no 
significant lymphadenopathy  
     
Fig 22: 73 year old gentleman diagnosed to have right sided carcinoma Tongue , the lesion measuring  5.3 x 5.2 cm ,post 
treatment there is increase in the bulk of the lesion measuring 9 x 5.5 cm and edema suggestive of disease progression. 
 
 
65 
 
4.61 SYMPTOM ASSESMENT: 
On first follow up all the six patients complained of dryness of mouth, difficulty in swallowing 
with occasional choking sensation and tastelessness.   
Pain control was adequate at the first follow up.  Five   patients had good pain control with STEP 
2 analgesics and one patient with STEP 1 analgesics.  
Out of five patients, four patients had severe pain at three months post treatment. They required 
initiation of Morphine, the doses ranging from 30 to 50 mg per day. 
 
4.62 PERFORMANCE SCORE: 
Post treatment the performance score worsened to ECOG 3 from ECOG 2 in three (50 %) 
patients.  It remained the same in three patients (50 %) (ECOG 2 in two patients and ECOG 1 in 
one patient).  
 
 4.63 ASSESMENT OF QUALITY OF LIFE: 
Quality of life was assessed in the patients with the help of  EORTC questionnaires. The 
questionnaire had two parts, one to assess the functional,  general symptomatology, global health 
and the second one was used to assess the site specific functions affected by radiotherapy in head 
and neck cancers. 
Table 15: Comparative statistics of functional, symptom scale global health scale pre and post RT: 
Scale Pre RT Mean values Post RT mean values 
Functional scale 73.71 40.75 
Symptom scale 32.70 51.93 
Global health scale 36.10 30.55 
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The mean value of the   functional scale, global health scale had decreased and means value of 
the symptom scale had increased post treatment. There was no statistically significant difference 
pre and post RT in the general health scale probably due to less sample size. 
Table 16: Comparative statistics of symptom wise scales pre and post RT (six weeks): 
Scores Pre RT Mean 
values 
Post RT mean values 
Pain  scores 40.2750 63.88 
Swallowing  31.90 76.38 
Senses 24.99 61.0 
speech 33.2 57.3 
social eating 29.1 69.4 
Social contact 26.6 49.9 
Sexuality 44.4 66.6 
Teeth 11.1 33.3 
Opening mouth 33.3 72.7 
Dry mouth 38.8 72.2 
Sticky saliva 44.4 77.7 
Cough 44.4 72.2 
Felt ill 55.5 66.6 
Pain killers 83.3 83.3 
Nutritional supplements 16.6 50.0 
Feeding tube 0.00 66.6 
Weight loss 100 83 
Weight gain 0.00 16.6 
 
The quality of life was assessed at six weeks   by assessment of several functions and symptoms.  
Majority of the patients complained of sticky salivation, dry mouth, difficulty in opening the 
mouth and difficulty in eating.  Many of them had to depend on ryles tube feeding or to take 
liquid diets orally. 
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The p values of mean scores of swallowing and social eating were significant. The rest of the p 
values were not significant. 
4.64 SURVIVAL: 
The median overall survival was 26   weeks (21.5 – 30.5 weeks). The median progression free 
survival was 5 months. 
 
Figure 23 showing Kaplan meier survival analysis with median overall  survival of 26 weeks 
One patient who was diagnosed to have carcinoma   hypopharynx stage T2N3M0 had partial 
regression of the disease at six weeks and complete response at three months and has a disease 
free survival of 25 weeks.  
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4.7 RETROSPECTIVE ANALYSIS OF PATIENTS WHO WERE TREATED WITH 
RADICAL CHEMO IRRADIATION: 
The charts of ten patients diagnosed to have locally advanced head and  neck cancers were 
retrospectively analyzed . The mean age of the patients was  46 years  and range was 30 – 70 
years  All of them were diagnosed to have stage 4 cancers( 70 % of stage 1V A cancers and  30 
% of stage 1V B cancers respectively).  The subsites were equally distributed among oropharynx, 
hypopharynx and tongue three in each and one patient was diagnosed to have carcinoma 
supraglottis. All of them received 66 Gy in 33 fractions with conventional fractionation along 
with concurrent weekly  Cisplatin. 
4.71 RADIOTHERAPY TREATMENT DETAILS: 
All   the patients except one completed the planned treatment.   There was no break in therapy in 
6 (60%)   patients. The remaining 4 patients who had break in radiotherapy had only a single 
break and the major cause was mucositis (30% grade 3 and 10 % grade 4).  Among the four 
patients two had break of 4 days, one of 9 days and one of 12 days and majority of the breaks 
were in the fourth and the sixth weeks.  Two patients completed with 61/2 weeks, three patients 
within 7 weeks and three patients within 8 weeks.  One patient completed treatment in 9 weeks. 
One patient discontinued treatment because of bilateral pneumonia, electrolyte imbalance and 
prolonged hospitalization. 
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Table 17: Duration of radiotherapy, treatment breaks, discontinuation and contributing reasons: 
S.no Duration of 
radiotherapy 
Breaks in 
treatment 
Duration 
of break 
Week of 
break  
Reasons Discontinuation 
Pt 1 6 weeks 3 
days 
Nil - - - - 
Pt 2 7 weeks yes 2 days Week 4 LRTI*  
Pt 3 7 weeks Nil - - - - 
Pt 4 7 weeks Nil - - -  
Pt 5 9 weeks yes 9 days Week 6  Gr 4 mucositis  
Pt 6 8 weeks yes 4 days  Week 6 Gr 3 mucositis  
Pt 7 5 weeks 4 
days 
- - - - Discontinued RT 
due to pneumonia 
Pt 8 8 weeks yes 4 Week 6 Gr 3mucositis  
Pt 9 6 weeks 4 
days 
nil - - -  
Pt 10 8 weeks yes 12 Week 4 Gr 3mucositis  
*lower respiratory tract infection 
4.72 CHEMOTHERAPY DETAILS: 
 
 The majority of causes for discontinuation of chemotherapy were  persistent higher grades of 
mucositis(40%), infection (20%), haematological toxicity (20%), worsening of renal 
function(10%),and allergic reaction to first chemotherapy(10%). 
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Table 18:Details  of planned chemotherapy cycles and reasons for deviation from the planned treatment: 
S.No Chemotherapy cycles 
planned 
Chemotherapy 
cycles received  
reasons 
Pt 1 6 3 LRTI*  
Pt 2 6 2 pneumonia 
Pt 3 6 1 Allergic reaction 
Pt 4 6 4 URTI# and mucositis 
Pt 5 6 4 Mucositis 
Pt 6 6 4 mucositis 
Pt 7 6 4 Low creat clearance 
Pt 8 6 4 mucositis 
Pt 9 6 2 Haematological 
toxicity 
Pt 10 6 6 - 
Abbreviations:*lower respiratory tract infection, #upper respiratory tract infection 
4.73 RYLES TUBE FEEDING: 
 Six patients required ryles tube feeding due to odynophagia and poor oral intake. 
4.74 HOSPITALISATION: 
 Two patients were hospitalized for duration of   8 and 12 days respectively in the fourth and 
fifth weeks for management of pneumonia.  Among   them one patient discontinued radiotherapy 
and the rest continued treatment.  
4.75 HAEMATOLOGICAL TOXICITY: 
Two patients had hematological toxicity because of which further chemotherapy was 
discontinued. 
Table 19: Hematological toxicity in patients who received chemotherapy 
Pt .No Hematological toxicity  Week of treatment No of cycles of 
chemotherapy 
1  Low WBC count (grade 1) Week 4 4 cycles  
2 Low WBC count and 
Thrombocytopenia(grade 1) 
Week 5 2 cycles 
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4.76 RESPONSE ASSESSMENT  AT SIX WEEKS: 
Response to treatment was assessed by clinical examination or by NPL scopy. At six weeks four 
patients had no disease clinically both at the primary and the nodal site.  Four patients had   no 
disease at the primary but had residual at the nodal site.  One patient had no nodal disease and 
had disease at the primary site. The response of one patient could not be assessed as he could not 
complete the treatment due to poor general condition.  
Table 20:  Response details of patients at six weeks 
Pt No Primary site Nodal disease 
Pt 1 No disease Residual present 
Pt 2 No disease  No disease 
Pt 3 No disease Residual present 
Pt 4 No disease Residual present 
Pt 5 Residual present No disease 
Pt 6 No disease No disease 
Pt 7 Not assessable Not assessable 
Pt 8 Residual present No disease 
Pt 9 No disease  No disease  
Pt 10 No disease  No disease  
4.77 RESPONSE ASSESSMENT AT THREE MONTHS: 
Response evaluation to treatment after three months showed complete response in 4 patients, 
partial response in 3 patients and progressive disease in one patient. Among the remaining two 
one patient did not complete the treatment and the other did not come for follow up. 
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Table 21 : Response details of the patients at three months 
Pt NO Response of primary 
site at 3 months  
Nodal Response  
at 3 months  
Radiological response Comments 
Pt 1 No disease Residual present Partial response PR# 
Pt 2 No disease clinically No disease Complete response CR* 
Pt 3 Not available Not available - - 
Pt 4 No disease Residual present Partial response PR# 
Pt 5 Recurrence No disease Progressive disease PD$ 
Pt 6 No disease No disease Complete response CR* 
Pt 7 Not assessable Not assessable -  
Pt 8 Residual present No disease  PR# 
Pt 9 No disease c No disease complete response CR* 
Pt 10 No disease c No disease 
clinically 
 CR* 
Abbreviations: CR*: complete response, PR#: partial response, PD$: progressive disease 
4.78 SURVIVAL ANALYSIS: 
The median overall survival was12.5 and the median Progression free survival was 11.5 months. 
4.8 RETROSPECTIVE ANALYSIS OF PATIENTS WHO WERE TREATED WITH   6/7 
FRACTIONATION: 
We had retrospectively reviewed data of 10 patients treated with 6/7 fractionation. This data is 
taken from the study done in our institution. Ten patients with inoperable head and neck cancer 
unfit for concurrent chemo irradiation were included in this study.  The mean age was 59.3 years. 
Primary site was Oropharynx (7), oral cavity (1), hypopharynx (1) and larynx. All patients had 
advanced inoperable lesions (80% IV A, 20 % III). All the patients completed treatment the 
planned treatment. The mean duration was 45.6 days (The mean duration was 45.6 days 
compared to planned duration of 37 days. Only one patient required hospitalization for 
supportive care. Grade III radiation mucositis was observed in 4 patients (36.36%). There was no 
incidence of significant hematological toxicity. Clinical assessment of primary lesion at the end-
of-RT showed disease regression in all cases. 
73 
 
5. DISCUSSION 
     Locally advanced head and neck cancers constitute about 25 % of the cancer burden in our 
country (82).  About 70 % of head and neck cancer patients present in locally advanced stage 
(83). The five year survival rates are 32 % for stage IVA,  and 25% for stage IV B (84) with a 
median survival of about 12 months (85).  Response of these patients to aggressive measures 
including chemo irradiation is poor with treatment related toxicities (86).  In view of this, 
achieving good palliation of distressing symptoms with minimal toxicity and reasonably lesser 
duration regimens (87) is what is important and essential but poses a challenge.  Therefore the 
primary aim in these patients should be to improve the quality of life.   
Hyperthermia is a clinical treatment for malignant diseases in which tumour tissues are 
heated to a temperature of 40 – 42°C for 30 – 60 minutes. The biological rationale of addition of 
hyperthermia is that it acts as a potent radio sensitizer.   This treatment is presumably beneficial 
for the hypoxic region of the tumor and to eliminate the radio resistant clone of cells.  The aim in 
this study was to evaluate the feasibility of addition of hyperthermia to radiation therapy for 
locally advanced inoperable head and neck cancer.  
              Huilgol et al (88) had  treated 28 patients with 70 Gy using conventional fractionation 
along with 5 to 7 sittings of hyperthermia once a week for 30 minutes prior to radiotherapy. We 
followed the above mentioned protocol   except for the pre cooling measures and invasive 
thermometry as described in their study. We have compared the results of our patients with the 
data obtained by retrospective analysis from similar patients treated by other regimens such as 40 
Gy in 10 fractions (2 fractions twice a week, hypofractionation ), patients treated with six 
fractions a week 
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(6/7,two fractions on the fifth day) and patient treated with  chemo irradiation (66 Gy in 33 
fractions along with weekly Cisplatin). 
              In this present study 60 % of patients completed the planned treatment and 30 % had 
completed without a break in the treatment.  Among the patients who had undergone chemo 
irradiation, 60 % completed without a break in treatment and 73 % of patients treated with 
hypofractionated radiotherapy completed the treatment without a break. The incidence of 
mucositis and dermatitis was slightly higher in our patients when compared to that in other 
treatment regimens. The incidence of grade 3 mucositis, grade 4 mucositis and  grade 3 
dermatitis was 42%,  14 % and 28 % respectively in the present study, whereas in the patients 
treated by chemo irradiation it was 30 %,  10 % and nil respectively.   In the patients treated with 
40 Gy in 10 fractions the incidence of grade 3 mucositis and grade 3 dermatitis was 18 % and 3 
%respectively. The only treatment related toxicity in the patients treated with 6/7 fractionation 
was grade 3 mucositis in 36.36%. 
            The average duration of break in treatment was 10 days in our patients 
 and 6 days in the patients treated with chemo irradiation. The average total duration required for 
treatment was similar in both the studies (52.8 days). 
 
There were three deaths in the study, reasons being aspiration pneumonia in two patients   and 
sudden death in one patient. Two patients were hospitalized during treatment for an average 
duration of 11.5 days for treatment of aspiration pneumonia.  Out of them, one patient had 
progressive disease and was advised supportive care due to poor general condition who died later 
at home. The other patient could not recover from massive pneumonia and died of respiratory 
failure.  
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           The incidence of aspiration pneumonia was more in our patients with an incidence of 20 
%(2 out of 10 patients) , whereas the incidence in the literature is between 5 % to 7% (89)(90).  
The contributing factors could have been dysphagia, disturbances in swallowing function related 
to either the tumour, radiotherapy related edema or mucositis which have been described in 
literature. Our patients who had this complication had extensive local disease in the Tongue and 
hypopharynx. The incidence of   pneumonia requiring hospitalization (average duration was 12.5 
days) in the chemo irradiation study was 20 % (2 out of 10 patients). These patients also had 
primary disease in the Tongue and hypopharynx which is similar to our patients.  One patient 
among them was discharged after recovery but the other one could not continue further treatment 
and went home on supportive care. There were no reported deaths in the patients treated with 
chemo irradiation. Among the patients treated with 40 Gy in 10 fractions and 6/7 regimen only 
one patient in each study required hospitalization.  
                During the first follow up at six weeks post treatment, 5 patients had adequate pain 
control with STEP 2 analgesics and 1 patient with STEP 1 analgesics.  During second follow up 
at three months, 3 patients (50%) had worsening of pain requiring STEP 3 analgesics 
(Morphine), 2 patients continued to have pain control with STEP 2 analgesics and one patient  
had died.. Majority of the patients complained of difficulty in swallowing, dry mouth, difficulty 
in eating and restricted mouth opening.  The requirement of ryles tube had increased post 
treatment and almost all the patients tolerated only liquid diet. Post treatment the performance 
score worsened to ECOG 3 from ECOG 2 in three of the patients.  It remained the same in three 
patients (ECOG 2 in two patients and ECOG 1 in one patient). 
        In our study, at a follow up period of six weeks four patients had disease regression and two 
patients had disease progression. There was good response to therapy at the nodal site with 70%   
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mean reduction in the nodal size. Progression of disease in these 2 patients was noted in the form 
of increase in the disease at primary site and distant metastases in the lung.  
                  At three months all patients had progressive disease except one patient who had 
complete response both clinically and radiologically.  Progression was noted at the primary site 
in two patients. Metastatic disease was present in two patients, out of which one patient already 
had lung metastases who progressed to have liver lesions and the second patient had new onset 
lung metastases. CT scans done showed decrease in the mean nodal size of all patients which 
was statistically significant. The median overall survival was 26 weeks and the median 
progression free survival was 25 weeks. The patient who had complete response has a disease 
free survival of 25 weeks. 
Huilgol etal had done a study randomizing patients between hyperthermia and radiation. The 
treatment compliance was 82 % in their study. There was no reported toxicity of higher grades of 
dermatitis and mucositis in their study and therapy was well tolerated.  Response assesment was 
done after 10 days of completion of treatment. Complete response was observed in 22 of 28 
(78.6%) patients in their study.  Five deaths were reported in their study (18 %) which was 
unrelated to treatment. The median survival was 34.2 weeks. 
 In another randomized trial conducted by Datta etal , they had treated patients with 60 - 66 Gy 
using conventional fractionation with twice a week treatment with hyperthermia. Assesment was 
done at 8 weeks. Complete response was seen in 83% in the combined group and 60% in the 
patients who received only radiotherapy in stage 3 patients.  In stage 4 patients complete 
response was seen in 63% of patients who received the combined treatment and 36 % in the 
patients who received only radiotherapy.  At the end of 18 months 25 % of patients were disease 
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free when compared to 8 % in the control group. They did not report any higher grades of 
toxicity. 
In another randomized control study performed by Valdagni etal which has a five year follow up 
period (conducted from 1985 – 86), the radiotherapy dose was 64 – 70 Gy in 2.0 – 2.5 Gy per 
fraction, five times a week and hyperthermia was delivered twice a week.  In the combined arm, 
complete response was seen in 15/18 (83%),  2/18 (11 %) had progressive disease and 1/18 (6 %) 
had partial response at three months while in the radiotherapy only arm it was 9/22 (40%) ,  4/22 
(18 %) and 9/22 (40 %) respectively. The five year survival favored the combined arm over the 
radiotherapy only arm which was 53 .3% versus 0 % respectively. The incidence of distant 
metastases was 12.5 % in the combined arm and 24 % in the radiotherapy only arm. There were 
four deaths in the combined arm due to non - neoplastic causes. There were no significant acute 
toxicities and very minimal late toxicities (bone necrosis in two patients). 
In a study conducted by Amichetti etal (73), 15 patients diagnosed to have unknown primary 
with neck nodes were treated with radiotherapy and local microwave hyperthermia.  All the 
patients received   Radiotherapy (57.50 – 74.40 Gy) with 6 MV linear accelerator or cobalt 
machine. Hyperthermia also was added to radiotherapy twice a week for a total of 2 – 7 sessions 
with a desired temperature of 42. 5 °C.   Complete response was seen in nine (9/15) patients and 
4 patients had partial response (4/15) with an overall response rate of 86.5 %.  The reported acute 
and late toxicities were mild.   Distant metastases developed in 5 patients who died because of 
the disease, nodal disease recurred in 2 patients and the remaining 2 patients died of other 
unrelated causes. This study showed benefit of hyperthermia when added to radiotherapy in 
patients who have unknown primary with large metastatic neck nodes. 
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In another study conducted by Arcangeli etal (91) complete response rates were 79% and 42% in 
the patients who received combined treatment and radiotherapy only respectively. They reported 
local control rates of 58 % and 14 % at the end of 28 months. 
                  The total duration of treatment, average duration of hospitalization and  the duration 
of the longest break in radiotherapy were almost similar in our patients and those treated with 
chemo irradiation.  The published results of a study conducted in our institution of 
hypofractionated radiotherapy (40 Gy in 10 fractions treated twice a week) showed better results 
in terms of palliation of pain (30 % in our patients and 12 % of patients who received 40 Gy in 
10 fractions required Morphine after completion of treatment), and other distressing 
symptoms(82). The performance status worsened in 50 % in the present versus 7 % of patients in 
the study treated with hypofractionated radiotherapy.  In our study though the symptoms were 
palliated for a limited duration, there was no improvement in quality of life beyond a short 
period (2 months).  There was not much of benefit in the physical, functional and social 
wellbeing of the patients post treatment.  Though there was considerable nodal response, this did 
not translate into increased local control rates at the primary, prevention of metastases and 
improved progression free survival rates.  
The reasons for these outcomes in this study might be a combinations of factors like improper 
and in homogenous thermal dose distribution, probable thermo tolerance, poor general condition 
of the patient, extensive local disease (N2, N3  disease) and the site of primary disease. The 
necessity of thermal dosimetry  in hyperthermia study was emphasized by  Manning et al (92), 
who concluded that only then, response to hyperthermia can be effectively evaluated and 
optimized.  The main aim of palliation could not be achieved in our study and the procedure of 
delivering hyperthermia followed by radiotherapy prolongs the treatment time and is 
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cumbersome. Therefore when there are other palliative radiotherapy regimens (of shorter 
duration, less difficult to carry out, less toxicity) the utility of hyperthermia along with 
conventional fractionation (longer duration) would not be an ideal option in a busy oncology 
centre. 
LIMITATIONS OF THE STUDY: 
1. There were more number of patients with primaries from the hypopharynx, locally advanced 
disease and poor performance status. This selection bias could have probably contributed to more 
incidence of aspiration pneumonia, more toxicity and poor outcomes. 
2. Lack of precooling measures might have added to more local reactions and acute toxicity.   
Lack of thermal dosimetry is a main disadvantage which might have helped to analyze the 
temperature distribution and would have avoided non homogeneity. 
3. This treatment is technically difficult and time consuming as it requires 30 minutes for each 
sitting under technical supervision. 
4. Cannot conclude on the benefits or inferiority of this treatment in view of less sample size. 
. 
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6.CONCLUSIONS 
 
1. Hyperthermia treatment along with radiation resulted in more acute toxicity. 
2. Moderate pain relief was achieved but this lasted only for a very short duration. 
3. Hyperthermia studies might produce better results when conducted with more well planned 
adequate infrastructure, thermometric dosimetry and meticulous monitoring of temperature. 
4. Response at the nodal site was good and so may be beneficial for patients with large fixed 
nodes. Therefore this could be considered for such patients, but should be carried out with the 
required facilities to have minimal and acceptable acute and late toxicity.  
5. The sample size was not adequate to draw conclusions regarding response to therapy. 
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Appendix 3 
Department Of Radiation Oncology, Unit II 
Christian Medical College & Hospital, Vellore 
Information sheet for participants 
Study Title :  A pilot study to evaluate the feasibility, tolerability and efficacy of addition of 
hyperthermia with external beam radiotherapy [EBRT] on patients of locally advanced non- 
metastatic inoperable head and neck cancer for palliation of symptoms. 
Study No            :       Subject’s Name      : 
 
Subject’s Initial :                                                              Date of Birth /Age  : 
You are being requested to participate in this study to see if you will tolerate the addition of hyperthermia to 
radiation therapy and to check to what extent this can cause reduction in size of the cancer. 
1. What is this study about? 
This study aims to test how well the addition of hyperthermia or heating to radiation therapy in patients diagnosed to 
have carcinoma of the head and neck is tolerated. The study will also look at how your disease is controlled after 
completion of treatment. 
 
2. How does Hyperthermia work? 
Hyperthermia is mild heating of the tumor area once weekly before the radiation therapy. It is known to increase 
blood circulation to the tumor. Radiation therapy needs good blood circulation to tumor to act properly. Therefore 
the tumor is expected to respond better to the radiation therapy when hyperthermia is added. Moreover, there are 
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evidence that there are some damage to the proteins and DNA during the process which help in selectively killing 
the tumor tissue. 
3. What is done in the study? 
After the diagnosis is confirmed and you are planned for radiation, you will be along with radiation therapy  
additional treatment with hyperthermia. Hyperthermia will involve mild heating of the tumor once every week 
before the radiation therapy to up to 40 degree Celsius. This would just provide warmth in the tumor area. 
Hyperthermia is expected to cause minimal side effects. It may be added that water boils at 100 degree Celsius. 
Radiation therapy is usually given five days in a week (Monday to Friday) for about seven weeks.  Hyperthermia is 
delivered once a week for thirty minutes half an hour before radiotherapy with the help of a hyperthermia machine.  
Care is taken care the temperature is not exceeded very high with the help of a thermometer. You will undergo 
check up once a week to assess whether you are tolerating the treatment well and check for any side effects. You 
will also be asked to answer a set of questions at the beginning and completion of the treatment regarding your 
symptoms. 
4. What are the side effects of the treatment? 
Radiation therapy has side effects. Although hyperthermia is not known to increase these side effects, it can 
potentiate them. The side effects of hyperthermia are feeling of warmth at the local area while on treatment 
darkening of the skin color.  There may be some increase in the radiation dermatitis and radiation mucositis.  
5. Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to withdraw permission to 
participate in this study. If you do so, this will not affect your usual treatment at this hospital in any way. In addition, 
if you experience any serious side effects or your condition worsens, the study will be stopped and you may be given 
additional treatment.  
6. What will happen if you develop any study related injury? 
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We do not expect any injury to happen to you but if you do develop any side effects or problems due to the study, 
these will be treated at no cost to you.  The expenses incurred due to any sickness, hospitalization will be covered by 
the internal collaborative insurance provided by the institution. 
7. Will you have to pay for the study treatment?  
The study treatment or hyperthermia will be provided free of cost.  You are required to pay only for radiation, and 
investigations as required for radiotherapy.  
8. What happens after the study is over? 
Once the study is over, you will be kept on follow up. You will continue to receive the necessary follow up advise 
and treatment which is the standard of care like any other patient.  After six weeks of the treatment a scopy will be 
done and after three months a CT scan will be done for assessment of the disease status. 
   9.   Will your personal details be kept confidential? 
The results of this study might be published in a medical journal but you will not be identified by name in any 
publication or presentation of results. However, your medical notes may be reviewed by people associated with the 
study, without your additional permission, should you decide to participate in this study.  
 
Informed consent form 
 
Study Number:   
Subject’s Initials:       _________             Subject’s Name: _________________________ 
Date of Birth____/____/______(DD/MM/YYYY) / Age: _______yrs  
 
Study Title : A pilot study to evaluate the feasibility, tolerability and efficacy of addition of hyperthermia with external beam 
radiotherapy [EBRT] on patients of locally advanced non- metastatic inoperable head and neck cancer for palliation of 
symptoms. 
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 (i) I confirm that I have read and understood the information sheet dated _________ for the above study and 
have had the opportunity to ask questions.   [            ] 
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected    [            ]                                                                                                                               
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, the Ethics 
Committee and the regulatory authorities will not need my permission to look at my health records both in 
respect of the current study and any further research that may be conducted in relation to it, even if I withdraw 
from the trial. I agree to this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published.  [            ]                                                                                           
(iv) I agree not to restrict the use of any data or results that arise from this study provided such a use is only for 
scientific purpose(s)   [        ] 
(v) I agree to take part in the above study.     [         ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
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Appendix 4 
CLINICAL RESEARCH FORM (CRF) 
HYPERTHERMIA AND RADIOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK CANCERS 
Study number: 
Serial number of the patient: 
Hospital number:                                                                                                     RT number: 
Name of the patient: 
Age: 
Gender: 
Local address:                                                                            Permanent address: 
 
 
Occupation: 
Marital status: 
Education: 
Phone Number: 
Socioeconomic status: 
 
Diagnosis: 
 
Patient details: 
Chief complaints: 
 
History and presenting illness: 
 
Past history: 
 
Family history: 
 
Personal history: 
 
Treatment history: 
Outside Investigations/Diagnosis: 
 
Surgery – (At CMCH/Outside) 
Chemotherapy – (At CMCH/ Outside) 
Radiotherapy - (At CMCH/ Outside)   
 
Clinical examination: 
Vital signs: 
Pulse:                         Blood pressure:                              Respiration:                         Temperature: 
 
Ht:                               Wt:                                                   BSA:                                      Creatinine clearance 
 
General examination: 
 
Ryles tube: 
Tracheostomy tube: 
IDL FINDINGS: 
 
LOCAL EXAMINATION: 
 
NPL SCOPY FINDINGS: 
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NECK EXAMINATION: 
                RIGHT NECK               LEFT NECK 
LEVEL AND SIZE   
NUMBER   
TENDER /NON TENDER   
CONSISTENCY 
(HARD/FIRM/SOFT) 
  
MOBILITY (MOBILE/ FIXED)   
 
SKIN OVER THE NODES 
  
 
SYSTEMIC EXAMINATION: 
INVESTIGATIONS : 
Biopsy No: 
Haemoglobin:                               Total blood counts:                                                      Differential count: 
Platelet count:                   Creatinine:                                          
Liver function tests: 
Blood borne Virus screen: 
Blood sugars: 
Chest xray: 
CT scan of head and neck: 
FINAL DIAGNOSIS AND STAGING: 
Date of starting  radiotherapy: 
Dates of delivering Hyperthermia: 
 
 
EORTC QOL H & N QUESTIONNAIRE:(PRE RT) 
WEEKLY ASSESMENT CHART: 
  WEEK 1 COMMENTS 
DAY/ DOSE   
HYPERTHERMIA SITTING   
Pain1   
Dryness of mouth2   
Nausea2   
Vomiting2   
Taste alteration2   
Difficulty in swallowing2   
Throat pain1    
1.  4.  
2.  5.  
3.  6.  
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Hoarseness of voice2   
Cough2   
Dyspnoea2   
Ear pain or Discharge2   
Nasal bleeding3   
Asthenia2   
Anorexia2   
Trismus2   
Loss f weight2   
Others   
EXAMINATION2   
Nasal cavity   
Lips   
Tongue   
Buccal Mucosa   
 
 
  
Alveolus   
Floor of mouth   
Hard palate   
Soft palate   
Tonsil   
Base of tongue   
PPW   
Candidiasis   
Skin reactions   
Others   
Weight   
Neck Separation   
 
HAEMATOLOGICAL PROFILE: 
 WEEK 1 COMMENTS 
Haemoglobin   
Total WBC   
Neutrophil count   
Lymphocyte count   
Platelet count   
 
 
NECK EXAMINATION: (WEEK 2) 
                RIGHT NECK               LEFT NECK 
LEVEL AND SIZE   
NUMBER   
TENDER /NON TENDER   
CONSISTENCY 
(HARD/FIRM/SOFT) 
  
MOBILITY (MOBILE/ FIXED)   
 
SKIN OVER THE NODES 
  
 
WEEKLY ASSESMENT CHART: 
  WEEK 2 COMMENTS 
DAY/ DOSE   
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HYPERTHERMIA SITTING   
Pain1   
Dryness of mouth2   
Nausea2   
Vomiting2   
Taste alteration2   
Difficulty in swallowing2   
Throat pain1    
Hoarseness of voice2   
Cough2   
Dyspnoea2   
Ear pain or Discharge2   
Nasal bleeding3   
Asthenia2   
Anorexia2   
Trismus2   
Loss f weight2   
Others   
EXAMINATION2   
Nasal cavity   
Lips   
Tongue   
Buccal Mucosa   
 
 
  
Alveolus   
Floor of mouth   
Hard palate   
Soft palate   
Tonsil   
Base of tongue   
PPW   
Candidiasis   
Skin reactions   
Others   
Weight   
Neck Separation   
 
HAEMATOLOGICAL PROFILE: 
 WEEK 2 COMMENTS 
Haemoglobin   
Total WBC   
Neutrophil count   
Lymphocyte count   
Platelet count   
 
NECK EXAMINATION: (WEEK 3) 
                RIGHT NECK               LEFT NECK 
LEVEL AND SIZE   
NUMBER   
TENDER /NON TENDER   
CONSISTENCY 
(HARD/FIRM/SOFT) 
  
MOBILITY (MOBILE/ FIXED)   
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SKIN OVER THE NODES 
 
WEEKLY ASSESMENT CHART: 
  WEEK 3 COMMENTS 
DAY/ DOSE   
HYPERTHERMIA SITTING   
Pain1   
Dryness of mouth2   
Nausea2   
Vomiting2   
Taste alteration2   
Difficulty in swallowing2   
Throat pain1    
Hoarseness of voice2   
Cough2   
Dyspnoea2   
Ear pain or Discharge2   
Nasal bleeding3   
Asthenia2   
Anorexia2   
Trismus2   
Loss f weight2   
Others   
EXAMINATION2   
Nasal cavity   
Lips   
Tongue   
Buccal Mucosa   
 
 
  
Alveolus   
Floor of mouth   
Hard palate   
Soft palate   
Tonsil   
Base of tongue   
PPW   
Candidiasis   
Skin reactions   
Others   
Weight   
Neck Separation   
 
HAEMATOLOGICAL PROFILE: 
 WEEK 3 COMMENTS 
Haemoglobin   
Total WBC   
Neutrophil count   
   
Platelet count   
 
NECK EXAMINATION: (WEEK 4) 
                RIGHT NECK               LEFT NECK 
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LEVEL AND SIZE   
NUMBER   
TENDER /NON TENDER   
CONSISTENCY 
(HARD/FIRM/SOFT) 
  
MOBILITY (MOBILE/ FIXED)   
 
SKIN OVER THE NODES 
  
 
WEEKLY ASSESMENT CHART: 
  WEEK 4 COMMENTS 
DAY/ DOSE   
HYPERTHERMIA SITTING   
Pain1   
Dryness of mouth2   
Nausea2   
Vomiting2   
Taste alteration2   
Difficulty in swallowing2   
Throat pain1    
Hoarseness of voice2   
Cough2   
Dyspnoea2   
Ear pain or Discharge2   
Nasal bleeding3   
Asthenia2   
Anorexia2   
Trismus2   
Loss f weight2   
Others   
EXAMINATION2   
Nasal cavity   
Lips   
Tongue   
Buccal Mucosa   
 
 
  
Alveolus   
Floor of mouth   
Hard palate   
Soft palate   
Tonsil   
Base of tongue   
PPW   
Candidiasis   
Skin reactions   
Others   
Weight   
Neck Separation   
 
HAEMATOLOGICAL PROFILE: 
 WEEK 4 COMMENTS 
Haemoglobin   
Total WBC   
Neutrophil count   
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Lymphocyte count   
Platelet count   
 
NECK EXAMINATION: (WEEK 5) 
                RIGHT NECK               LEFT NECK 
LEVEL AND SIZE   
NUMBER   
TENDER /NON TENDER   
CONSISTENCY 
(HARD/FIRM/SOFT) 
  
MOBILITY (MOBILE/ FIXED)   
 
SKIN OVER THE NODES 
  
 
WEEKLY ASSESMENT CHART: 
  WEEK 5 COMMENTS 
DAY/ DOSE   
HYPERTHERMIA SITTING   
Pain1   
Dryness of mouth2   
Nausea2   
Vomiting2   
Taste alteration2   
Difficulty in swallowing2   
Throat pain1    
Hoarseness of voice2   
Cough2   
Dyspnoea2   
Ear pain or Discharge2   
Nasal bleeding3   
Asthenia2   
Anorexia2   
Trismus2   
Loss f weight2   
Others   
EXAMINATION2   
Nasal cavity   
Lips   
Tongue   
Buccal Mucosa   
 
 
  
Alveolus   
Floor of mouth   
Hard palate   
Soft palate   
Tonsil   
Base of tongue   
PPW   
Candidiasis   
Skin reactions   
Others   
Weight   
Neck Separation   
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HAEMATOLOGICAL PROFILE: 
 WEEK 5 COMMENTS 
Haemoglobin   
Total WBC   
Neutrophil count   
Lymphocyte count   
Platelet count   
 
NECK EXAMINATION: (WEEK 6) 
                RIGHT NECK               LEFT NECK 
LEVEL AND SIZE   
NUMBER   
TENDER /NON TENDER   
CONSISTENCY 
(HARD/FIRM/SOFT) 
  
MOBILITY (MOBILE/ FIXED)   
 
SKIN OVER THE NODES 
  
WEEKLY ASSESMENT CHART: 
  WEEK 6 COMMENTS 
DAY/ DOSE   
HYPERTHERMIA SITTING   
Pain1   
Dryness of mouth2   
Nausea2   
Vomiting2   
Taste alteration2   
Difficulty in swallowing2   
Throat pain1    
Hoarseness of voice2   
Cough2   
Dyspnoea2   
Ear pain or Discharge2   
Nasal bleeding3   
Asthenia2   
Anorexia2   
Trismus2   
Loss f weight2   
Others   
EXAMINATION2   
Nasal cavity   
Lips   
Tongue   
Buccal Mucosa   
 
 
  
Alveolus   
Floor of mouth   
Hard palate   
Soft palate   
Tonsil   
Base of tongue   
PPW   
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Candidiasis   
Skin reactions   
Others   
Weight   
Neck Separation   
 
HAEMATOLOGICAL PROFILE: 
 WEEK 6 COMMENTS 
Haemoglobin   
Total WBC   
Neutrophil count   
Lymphocyte count   
Platelet count   
 
NECK EXAMINATION: (WEEK 7) 
                RIGHT NECK               LEFT NECK 
LEVEL AND SIZE   
NUMBER   
TENDER /NON TENDER   
CONSISTENCY 
(HARD/FIRM/SOFT) 
  
MOBILITY (MOBILE/ FIXED)   
 
SKIN OVER THE NODES 
  
 
WEEKLY ASSESMENT CHART: 
  WEEK 7 COMMENTS 
DAY/ DOSE   
HYPERTHERMIA SITTING   
Pain1   
Dryness of mouth2   
Nausea2   
Vomiting2   
Taste alteration2   
Difficulty in swallowing2   
Throat pain1    
Hoarseness of voice2   
Cough2   
Dyspnoea2   
Ear pain or Discharge2   
Nasal bleeding3   
Asthenia2   
Anorexia2   
Trismus2   
Loss f weight2   
Others   
EXAMINATION2   
Nasal cavity   
Lips   
Tongue   
Buccal Mucosa   
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Alveolus   
Floor of mouth   
Hard palate   
Soft palate   
Tonsil   
Base of tongue   
PPW   
Candidiasis   
Skin reactions   
Others   
Weight   
Neck Separation   
 
HAEMATOLOGICAL PROFILE: 
 WEEK 7 COMMENTS 
Haemoglobin   
Total WBC   
Neutrophil count   
Lymphocyte count   
Platelet count   
 
 NOTE: 
1. Pain will be graded according to Numerical rating scale (scale from 1 to 10) 
2. Toxicity(Dermatitis, Mucositis, Haematological) will be graded according to CTCAE criteria(1 to 4) 
3. Quality of life will be assessed by EORTC QOL H& N questionnaire 
 
  
END OF HTRT ASSESMENT: 
Clinical examination: 
Vital signs: 
Pulse:                         Blood pressure:                              Respiration:                         Temperature: 
 
Ht:                               Wt:                                                   BSA:                                      Creatinine clearance 
 
General examination: 
 
 
 
Ryles tube: 
Tracheostomy tube: 
IDL FINDINGS: 
LOCAL EXAMINATION: 
 
 
 
 
NPL SCOPY FINDINGS: 
NECK EXAMINATION: 
                RIGHT NECK               LEFT NECK 
LEVEL AND SIZE   
NUMBER   
TENDER /NON TENDER   
CONSISTENCY 
(HARD/FIRM/SOFT) 
  
MOBILITY (MOBILE/ FIXED)   
SKIN OVER THE NODES   
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SYSTEMIC EXAMINATION: 
INVESTIGATIONS : 
Haemoglobin:                    Total blood counts:                          Differential count: 
Platelet count:                   Creatinine:                                          
EORTC QOL H& N QUESTIONNAIRE (AFTER RT) 
 
 
AFTER SIX WEEKS ASSESMENT: 
Clinical examination: 
Vital signs: 
Pulse:                         Blood pressure:                              Respiration:                         Temperature: 
 
Ht:                               Wt:                                                   BSA:                                      Creatinine clearance 
 
General examination: 
 
 
 
Ryles tube: 
Tracheostomy tube: 
IDL FINDINGS: 
LOCAL EXAMINATION: 
 
 
 
NPL SCOPY FINDINGS: 
 
 
NECK EXAMINATION: 
                RIGHT NECK               LEFT NECK 
LEVEL AND SIZE   
NUMBER   
TENDER /NON TENDER   
CONSISTENCY 
(HARD/FIRM/SOFT) 
  
MOBILITY (MOBILE/ FIXED)   
SKIN OVER THE NODES   
SYSTEMIC EXAMINATION: 
INVESTIGATIONS : 
Haemoglobin:                    Total blood counts:                          Differential count: 
Platelet count:                   Creatinine:                                          
EORTC QOL H& N QUESTIONNAIRE (SIX WEEKS AFTER RT) 
AFTER THREE MONTHS: 
Clinical examination: 
Vital signs: 
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Pulse:                         Blood pressure:                              Respiration:                         Temperature: 
 
Ht:                               Wt:                                                   BSA:                                      Creatinine clearance 
 
General examination: 
 
Ryles tube: 
Tracheostomy tube: 
IDL FINDINGS: 
 
LOCAL EXAMINATION: 
 
NPL SCOPY FINDINGS: 
 
NECK EXAMINATION: 
                RIGHT NECK               LEFT NECK 
LEVEL AND SIZE   
NUMBER   
TENDER /NON TENDER   
CONSISTENCY       (HARD/FIRM/SOFT)   
MOBILITY (MOBILE/ FIXED)   
SKIN OVER THE NODES   
 
SYSTEMIC EXAMINATION: 
INVESTIGATIONS : 
Haemoglobin:                    Total blood counts:                          Differential count: 
Platelet count:                   Creatinine:                  
CT scan :                         
EORTC QOL H& N QUESTIONNAIRE (THREE MONTHS AFTER RT) 
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Appendix 6 
RTOG CRITERIA FOR TOXICITY GRADING: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 [ 0 ] [ 1 ] [ 2 ] [ 3 ] [ 4 ] 
SKIN 
No 
change 
over 
baseline 
Follicular, faint 
or dull 
erythema/ 
epilation/dry 
desquamation/ 
decreased 
sweating 
Tender or bright 
erythema, patchy 
moist 
desquamation/ 
moderate edema 
Confluent, 
moist 
desquamatiom 
other than skin 
folds, pitting 
edema 
Ulceration, 
hemorrhage, 
necrosis 
MUCOUS 
MEMBRANE
No 
change 
over 
baseline 
Injection/ may 
experience mild 
pain not 
requiring 
analgesic 
Patchy mucositis 
which may 
produce an 
inflammatory 
serosanguinitis 
discharge/ may 
experience 
moderate pain 
requiring 
analgesia 
Confluent 
fibrinous 
mucositis/ may 
include severe 
pain requiring 
narcotic 
Ulceration, 
hemorrhage 
or necrosis 
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Appendix 7 : CTCAE version 4 
 
 1 2 3 4 5 
Nausea Loss of appetite 
without 
alteration in 
eating habits 
Oral intake 
decreased without 
significant weight 
loss, 
dehydration or 
malnutrition 
Inadequate oral 
caloric or fluid 
intake; tube 
feeding, TPN, or 
hospitalization 
indicated 
 
  
Hoarseness 
of voice 
Mild or 
intermittent 
voice 
change; fully 
understandable; 
self-resolves 
Moderate or 
persistent voice 
changes; may 
require 
occasional 
repetition but 
understandable 
on telephone; 
medical 
evaluation 
indicated 
Severe voice 
changes including 
predominantly 
whispered 
speech 
  
Dysphagia Symptomatic, 
able to eat 
regular diet 
Symptomatic and 
altered 
eating/swallowing 
Severely altered 
eating/swallowing; 
tube feeding 
or TPN or 
hospitalization 
indicated 
Life-
threatening 
consequences 
urgent 
intervention 
indicated 
 
Cough Mild symptoms; 
nonprescription 
intervention 
indicated 
Moderate 
symptoms, 
medical 
intervention 
indicated; limiting 
instrumental ADL 
Severe symptoms; 
limiting self 
care ADL 
  
Throat pain Mild pain Moderate pain; 
limiting 
instrumental ADL 
Severe pain; 
limiting self care 
ADL; limiting ability 
to swallow 
-  
Vomiting 1 - 2 episodes 
(separated by 5 
minutes) in 24 
hrs 
3 - 5 episodes 
(separated by 5 
minutes) in 24 hrs 
>=6 episodes 
(separated by 5 
minutes) in 24 hrs; 
tube feeding, 
TPN or 
hospitalization 
indicated 
Life-
threatening 
consequences; 
urgent 
intervention 
indicated 
death 
Anorexia Loss of appetite 
without 
alteration in 
eating habits 
Oral intake 
altered without 
significant weight 
loss or 
malnutrition; oral 
nutritional 
supplements 
indicated 
Associated with 
significant 
weight loss or 
malnutrition (e.g., 
inadequate oral 
caloric and/or 
fluid intake); tube 
feeding or 
TPN indicated 
Life-
threatening 
consequences; 
urgent 
intervention 
indicated 
Death 
Fatigue Fatigue relieved 
by rest 
Fatigue not 
relieved by rest; 
Fatigue not relieved 
by rest, 
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(CTCAE) Version 4.0 
Parameter Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Platelet count <LLN - 
75,000/mm3 
 
<75,000 - 
50,000/mm3;  
 
<50,000 - 
25,000/mm3;  
 
<25,000/mm3;  Death 
Anaemia Hemoglobin 
(Hgb) <LLN - 
10.0 g/dL; 
Hgb <10.0 - 
8.0 g/dL 
Hgb <8.0 
g/dL 
Life 
threatening 
consequences 
Death 
Neutrophil 
count 
decreased 
<LLN - 
1500/mm3 
 
<1500 - 
1000/mm3 
 
<1000 - 
500/mm3 
 
<500/mm3 Death 
 
 
 
 
 
 
 
 
 
 
 
 
 
limiting 
instrumental ADL 
limiting self care 
ADL 
115 
 
Appendix 8 
Response Evaluation Criteria in Solid Tumors (RECIST) Quick Reference: 
 
Eligibility 
Only patients with measurable disease at baseline should be included in protocols where objective tumor response is the primary 
endpoint.  
Measurable disease - the presence of at least one measurable lesion. If the measurable disease is restricted to a solitary lesion, its 
neoplastic nature should be confirmed by cytology/histology.  
Measurable lesions - lesions that can be accurately measured in at least one dimension with longest diameter  20 mm using 
conventional techniques or 10 mm with spiral CT scan. 
Non-measurable lesions - all other lesions, including small lesions (longest diameter <20 mm with conventional techniques or <10 
mm with spiral CT scan), i.e., bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory breast 
disease, lymphangitis cutis/pulmonis, cystic lesions, and also abdominal masses that are not confirmed and followed by imaging 
techniques; and. 
All measurements should be taken and recorded in metric notation, using a ruler or calipers. All baseline evaluations should be 
performed as closely as possible to the beginning of treatment and never more than 4 weeks before the beginning of the 
treatment.  
The same method of assessment and the same technique should be used to characterize each identified and reported lesion at 
baseline and during follow-up.  
Clinical lesions will only be considered measurable when they are superficial (e.g., skin nodules and palpable lymph nodes). For 
the case of skin lesions, documentation by color photography, including a ruler to estimate the size of the lesion, is 
recommended.  
Methods of Measurement –  
 
 CT and MRI are the best currently available and reproducible methods to measure target lesions selected for response 
assessment. Conventional CT and MRI should be performed with cuts of 10 mm or less in slice thickness contiguously. 
Spiral CT should be performed using a 5 mm contiguous reconstruction algorithm.  This applies to tumors of the chest, 
abdomen and pelvis. Head and neck tumors and those of extremities usually require specific protocols. 
 
Lesions on chest X-ray are acceptable as measurable lesions when they are clearly defined and surrounded by aerated lung. 
However, CT is preferable.  
 
When the primary endpoint of the study is objective response evaluation, ultrasound (US) should not be used to measure 
tumor lesions. It is, however, a possible alternative to clinical measurements of superficial palpable lymph nodes, subcutaneous 
lesions and thyroid nodules. US might also be useful to confirm the complete disappearance of superficial lesions usually 
assessed by clinical examination. 
 
The utilization of endoscopy and laparoscopy for objective tumor evaluation has not yet been fully and widely validated. Their 
uses in this specific context require sophisticated equipment and a high level of expertise that may only be available in some 
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centers. Therefore, the utilization of such techniques for objective tumor response should be restricted to validation purposes 
in specialized centers. However, such techniques can be useful in confirming complete pathological response when biopsies are 
obtained. 
 
Tumor markers alone cannot be used to assess response.  If markers are initially above the upper normal limit, they must 
normalize for a patient to be considered in complete clinical response when all lesions have disappeared. 
 
Cytology and histology can be used to differentiate between PR and CR in rare cases (e.g., after treatment to differentiate 
between residual benign lesions and residual malignant lesions in tumor types such as germ cell tumors). 
Baseline documentation of “Target” and “Non-Target” lesions 
All measurable lesions up to a maximum of five lesions per organ and 10 lesions in total, representative of all involved organs 
should be identified as target lesions and  recorded and measured at baseline.  
Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate 
repeated measurements (either by imaging techniques or clinically).  
A sum of the longest diameter (LD) for all target lesions will be calculated and reported as the baseline sum LD. The baseline 
sum LD will be used as reference by which to characterize the objective tumor. 
All other lesions (or sites of disease) should be identified as non-target lesions and should also be recorded at baseline. 
Measurements of these lesions are not required, but the presence or absence of each should be noted throughout follow-up.  
Response Criteria 
Evaluation of target lesions 
* Complete Response (CR): Disappearance of all target lesions 
* Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline 
sum LD 
* Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest 
sum LD recorded since the treatment started or the appearance of one or more new lesions 
* Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as 
reference the smallest sum LD since the treatment started 
Evaluation of non-target lesions 
* Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level 
* Incomplete Response/          
Stable Disease (SD):  
Persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level 
above the normal limits 
* Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-
target lesions (1)  
Although a clear progression of “non target” lesions only is exceptional, in such circumstances, the opinion of the treating 
physician should prevail and the progression status should be confirmed later on by the review panel (or study chair). 
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Evaluation of best overall response 
The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence 
(taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best 
response assignment will depend on the achievement of both measurement and confirmation criteria  
 
Target lesions Non-Target lesions New Lesions Overall response 
CR CR No CR 
CR Incomplete response/SD No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
 
Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of 
disease progression at that time should be classified as having “symptomatic deterioration”. Every effort should be made to 
document the objective progression even after discontinuation of treatment.  
In some circumstances it may be difficult to distinguish residual disease from normal tissue. When the evaluation of complete 
response depends on this determination, it is recommended that the residual lesion be investigated (fine needle 
aspirate/biopsy) to confirm the complete response status. 
 
Confirmation 
The main goal of confirmation of objective response is to avoid overestimating the response rate observed.  In cases where 
confirmation of response is not feasible, it should be made clear when reporting the outcome of such studies that the 
responses are not confirmed. 
To be assigned a status of PR or CR, changes in tumor measurements must be confirmed by repeat assessments that should be 
performed no less than 4 weeks after the criteria for response are first met. Longer intervals as determined by the study 
protocol may also be appropriate.  
In the case of SD, follow-up measurements must have met the SD criteria at least once after study entry at a minimum interval 
(in general, not less than 6-8 weeks) that is defined in the study protocol  
Duration of overall response 
The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever status is 
recorded first) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest 
measurements recorded since the treatment started. 
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Duration of stable disease 
SD is measured from the start of the treatment until the criteria for disease progression are met, taking as reference the 
smallest measurements recorded since the treatment started.  
The clinical relevance of the duration of SD varies for different tumor types and grades. Therefore, it is highly recommended 
that the protocol specify the minimal time interval required between two measurements for determination of SD. This time 
interval should take into account the expected clinical benefit that such a status may bring to the population under study.  
Response review 
For trials where the response rate is the primary endpoint it is strongly recommended that all responses be reviewed by an 
expert(s) independent of the study at the study’s completion.  Simultaneous review of the patients’ files and radiological 
images is the best approach.  
Reporting of results 
All patients included in the study must be assessed for response to treatment, even if there are major protocol treatment 
deviations or if they are ineligible.  Each patient will be assigned one of the following categories: 1) complete response, 2) 
partial response, 3) stable disease, 4) progressive disease, 5) early death from malignant disease, 6) early death from toxicity, 7) 
early death because of other cause, or 9) unknown (not assessable, insufficient data). 
All of the patients who met the eligibility criteria should be included in the main analysis of the response rate.  Patients in 
response categories 4-9 should be considered as failing to respond to treatment (disease progression).  Thus, an incorrect 
treatment schedule or drug administration does not result in exclusion from the analysis of the response rate.  Precise 
definitions for categories 4-9 will be protocol specific. 
All conclusions should be based on all eligible patients. 
Subanalyses may then be performed on the basis of a subset of patients, excluding those for whom major protocol deviations 
have been identified (e.g., early death due to other reasons, early discontinuation of treatment, major protocol violations, etc.).  
However, these subanalyses may not serve as the basis for drawing conclusions concerning treatment efficacy, and the reasons 
for excluding patients from the analysis should be clearly reported.   
The 95% confidence intervals should be provided. 
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STATISTICAL ANALYSIS: 
 
Analysis of quality of life scales: 			 
Scales Mean N Std. Deviation 
Std. Error 
Mean 
 Functional Pre RT 73.7183 6 12.78805 5.22070 
Functional Post RT 40.7567 6 38.23184 15.60809 
 Symptom Pre RT 32.7033 6 15.63838 6.38434 
Symptom Post RT 51.9383 6 29.48609 12.03765 
 Global PreRT 36.1033 6 25.64769 10.47062 
Global Post RT 30.5533 6 31.47403 12.84922 
 
Paired Samples Correlations 
 
  N Correlation Sig. 
Pair 
1 
funcprert & 
funcpostrt 5 .042 .947 
Pair 
2 
symptomprert & 
symptompostt 5 -.645 .240 
Pair 
3 
globalprert & 
globalpostt 5 .152 .807 
     
     
 Paired Differences t df 
Sig. (2-
tailed) 
  Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
95% Confidence 
Interval of the 
Difference Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
      Lower Upper   
Pair 
1 
HNPA Pre RT - 
HNPA Post RT 
-
23.60667 59.72459 24.38246 -86.28377 39.07044 -.968 5 .377 
Pair 
2 
HNSW Pre RT 
- HNSW Post 
RT 
-
44.48167 36.00084 14.69728 -82.26223 -6.70110 
-
3.027 5 .029 
Pair 
3 
HNSE Pre RT - 
HNSE Post RT 
-
36.10667 48.76673 19.90893 -87.28421 15.07088 
-
1.814 5 .129 
Pair 
4 
HNSP Pre RT - 
HNSP Post RT 
-
24.06000 64.15814 26.19245 -91.38984 43.26984 -.919 5 .400 
Pair 
5 
HNSO Pre RT - 
HNSO Post RT 
-
40.29000 30.00284 12.24861 -71.77605 -8.80395 
-
3.289 5 .022 
Pair 
6 
HNSC  Pre RT 
- HNSC  Post 
RT 
-
23.32833 58.25391 23.78206 -84.46206 37.80539 -.981 5 .372 
Pair 
7 
HNSX  Pre RT 
- HNSX  post 
Rt 
-
22.22833 58.37935 23.83327 -83.49370 39.03704 -.933 5 .394 
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Pair 
8 
HNTE  Pre Rt - 
HNTE post RT 
-
22.22333 65.54433 26.75836 -91.00789 46.56122 -.831 5 .444 
Pair 
9 
HNON preRt - 
HNOM post Rt 
-
38.87667 61.17601 24.97500 
-
103.07695 25.32362 
-
1.557 5 .180 
Pair 
10 
HNDR pre Rt - 
HNDR post RT 
-
33.33333 76.01199 31.03176 
-
113.10302 46.43636 
-
1.074 5 .332 
Pair 
11 
HNSSpre Rt - 
HNSS post rt 
-
33.34000 69.92409 28.54639 
-
106.72083 40.04083 
-
1.168 5 .295 
Pair 
12 
HNCOpre rt - 
HNCOpost rt 
-
27.77333 71.23274 29.08065 
-
102.52751 46.98085 -.955 5 .383 
Pair 
13 
HNFI prert - 
HNFIpost rt 
-
11.10833 58.37212 23.83032 -72.36611 50.14945 -.466 5 .661 
 
 
 
 Statistical analyses between pre and post CT values 
  
CT PRE RT –
POST T P CT PRE RT –POST T N 
Z .000(a) -2.023(b) 
Asymp. Sig. 
(2-tailed) 1.000 .043 
a  The sum of negative ranks equals the sum of positive ranks. 
b  Based on positive ranks. 
c  Wilcoxon Signed Ranks Test 
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